Figure A): Illustrates the overall system architecture. Clients send requests to a set of replica servers that each run the same application and maintain synchronized state. Replicas communicate with one another through a dedicated replica network to exchange replication messages and maintain consistent ordering of requests. In addition, replicas receive a shared timing signal through a separate clock network, which keeps their clocks closely synchronized. Separating the client network, replica network, and clock synchronization channel enables replicas to coordinate communication and processing in a predictable, time-driven manner.

Figure B): Illustrates the scheduled communication model used between replicas. Figure B (left) shows the network topology and how replicas are connected through switches that forward messages between servers. Figure B (right) shows a time-based transmission schedule in which each replica is assigned specific time slots to broadcast messages. The schedule accounts for network delays and small clock differences so that packets arrive without causing congestion or queue buildup. By following this predetermined schedule, replicas exchange messages in a controlled sequence that enables deterministic system behavior.]]>Intellectual Property:

• Provisional Filed]]>Reference Media:
  • Newatia, K. et. al., NINeS, 2026 Mar 19; Article 26: 26:1 ]]>Desired Partnerships:
    • License
    • Co-Development]]>Docket #26-11452AndreasHaeberlenProfessorahae@cis.upenn.eduRobertGiffordProfessorrgif@seas.upenn.eduLinh Thi XuanPhanAssociate Professorlinhphan@cis.upenn.eduQingjieLuandylu@seas.upenn.eduKaranNewatiaPhD Studentknewatia@seas.upenn.eduData Science, Software, RobertLjungbergLicensing Officer, Physical Sciences and EngineeringPenn Center for Innovationrobertlj@upenn.edu Computer Information Systems]]>Falsehttps://www.canberra-ip.com/tech/Targeted_Nanoparticle-Mediated_HIF_Stabilization_in_Myeloid_Cells_for_Enhanced_Transplant_ToleranceSHORT DESCRIPTION
      A PEG-PPS nanoparticle technology for targeted delivery of roxadustat to myeloid cells to promote transplantation tolerance.
      INVENTORS
      • Edward Thorp*
        • Northwestern University Feinberg School of Medicine, Department of Pathology
      • Evan Scott*
        • McCormick School of Engineering, Department of Biomedical Engineering **Now at University of Virginia**
      • Matthew DeBerge
      * Principal Investigator

      NU Tech ID: NU 2023-184

      IP STATUS

      PCT Application pending (PCT/US2024/055220)

      DEVELOPMENT STAGE

      TRL-5 - Prototype Validated in Relevant Environment: Preclinical testing in mouse models validated immunomodulatory potential.

      BACKGROUND
      Heart and other solid-organ transplants are life-saving for patients with advanced organ failure, but long-term outcomes are limited by immune rejection of the foreign tissue. Strategies for treating this issue rely on broad immunosuppressants, but standard regimens (calcineurin inhibitors, antiproliferative agents, steroids, and mTOR inhibitors) are linked to serious complications, including infections, kidney damage, malignancies, metabolic disease, and accelerated graft vessel disease. There is a clear unmet need for new solutions that can preserve graft acceptance while reducing the long-term harms and practical burden of chronic immunosuppression. An attractive alternative is to target just the immune cells involved in organ rejection. Such a targeted approach would suppress activity locally around the transplant, without broad immunosuppressive effects, increasing likelihood of transplant acceptance, while decreasing side effects of therapies. Myeloid cells represent a particularly attractive target for these therapies.

      ABSTRACT
      Northwestern researchers developed a targeted nanoparticle platform that enhances transplant tolerance by increasing the activity of a protein called HIF‑2α in myeloid cells. The core product is a spherical micelle nanocarrier made from a PEG‑b‑PPS block copolymer that encapsulates a HIF‑2α‑inducing agent such as roxadustat, and is designed to specifically targets myeloid cells (i.e. monocytes and macrophages). In a murine heart transplant models using co-stimulatory blockade, the inventors show that this approach boosted HIF‑2α and CSF1R expression and promoted the development of tolerogenic macrophages, reduced damaging T‑cell responses, supported regulatory T cells, and improved cardiac allograft survival with less vessel damage and fewer donor‑specific antibodies while reducing some systemic effects of free roxadustat such as high erythropoietin levels. This technology represents a novel and more selective strategy for long‑term graft protection.

      APPLICATIONS

      • Adjunct therapy to standard immunosuppression in heart transplantation
      • Immune reprogramming to reduce rejection in solid‑organ and cell transplants 
      • Combination therapy with costimulatory‑blockade strategies 
      • Treatment of autoimmune or chronic inflammatory conditions

      ADVANTAGES

      • Enhanced tolerogenic response
      • Direct myeloid targeting

      PUBLICATIONS

      • Evan Scott, Edward Thorp et al, Hypoxia inducible factor 2α promotes tolerogenic macrophage development during cardiac transplantation through transcriptional regulation of colony stimulating factor 1 receptor, PNAS, 2024 Vol. 121 No. 26 e2319623121

      KEYWORDS
      Nanoparticles, roxadustat, transplantation tolerance, macrophage-targeting, immunomodulation, HIF stabilization, heart transplant, PEG-PPS, nanoparticle delivery, tolerogenic macrophages

      ]]>Thu, 07 May 2026 16:05:41 GMTdragos@northwestern.eduhttps://www.canberra-ip.com/tech/Targeted_Nanoparticle-Mediated_HIF_Stabilization_in_Myeloid_Cells_for_Enhanced_Transplant_Tolerance2023-184Thu, 07 May 2026 16:07:56 GMTDrug delivery, Immunotherapy, Nanoparticle, Therapeutics, Tolerance induction, Transplantation, MichaelFiskeInvention ManagerMED-NUINmichael.fiske@northwestern.edu Therapeutics]]>Falsehttps://www.canberra-ip.com/tech/Targeting_Autoimmunity-Associated_T_cells_via_AHR_Pathway_ControlSHORT DESCRIPTION
      Use of AHR agonists to inhibit pathogenic Tfh/Tph cell differentiation, potentially reducing disease activity.

      INVENTORS

      •  Jaehyuk Choi*
        • Northwestern University Feinberg School of Medicine, Department of Dermatology **(Now at UT Southwestern)**
      • Deepak Rao
        • Brigham and Women's Hospital, Department of Medicine (Division of Rheumatology, Inflammation, and Immunity) 
      • Calvin Law
        • Northwestern University Feinberg School of Medicine

      * Principal Investigator

      NU Tech ID: NU 2023-127

      IP STATUS

      US Patent pending

      DEVELOPMENT STAGE

      TRL-3 - Experimental Proof-of-Concept: Key functions have been demonstrated in controlled in vitro assays.

      
      BACKGROUND

      Autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren disease, or systemic sclerosis occur when the immune system attacks the body's own tissues, driving chronic inflammation and organ damage. SLE affects roughly 204,000 Americans, and RA affects about 10.6 million U.S. adults, with a disproportionate burden on women and on Black, Hispanic, and Indigenous communities. A central driver of these diseases is overactive T cells and B cells that leads to the generation of harmful autoantibodies. Current treatment relies on broad immune suppression and immune-modifying drugs, including hydroxychloroquine, steroids, immunosuppressants, and newer biologic therapies such as belimumab and anifrolumab. While these therapies can control disease for some patients, many still experience ongoing disease activity, flares, or incomplete responses, and long‑term steroid and immunosuppressant exposure carries significant safety concerns. Together, these shortcomings leave a substantial unmet need for new, mechanism-specific therapies that can achieve durable remission with fewer side effects.

      
      ABSTRACT
      Recently, T peripheral helper (Tph) cells, a specific population of B-cell-helping T cells marked by high output of the chemokine CXCL13, have been identified as a key driver of autoantibody production in lupus and RA. This therapeutic platform developed by Northwestern researchers  aims to shut down these autoimmune T cells by regulating their internal control switches rather than broadly shutting down the immune system. It identifies the aryl hydrocarbon receptor (AHR) and defined transcription factors as key regulators of a T-cell program that promotes B‑cell activation via a chemokine called CXCL13, which is linked to disease activity and antibody production in lupus and rheumatoid arthritis. The inventors show that activating AHR can reduce the formation and function of these CXCL13‑producing T cells and support an alternative T‑cell state associated with more balanced immune activity. The technology provides compositions and methods that use AHR agonists alone, combined with regulatory transcription factors (AHR, JUN, FOS, ATF3, FOSL1, FOSL2), or paired with CRISPR-based gene editing, to reduce the differentiation and activity of CXCL13-producing Tph and Tfh cells that drive autoantibody-mediated autoimmune disease. Gene-editing, cell-culture, genomic, and patient-sample studies indicate that AHR activity restrains the harmful lupus-associated program, while interferon signaling pushes cells in the opposite direction. In patient-linked analyses, blocking type I interferon signaling reduced a lupus-associated blood signal and shifted T-cell populations away from the disease-driving state, further supporting the pathway’s clinical relevance. This technology represents a potential first-in-class or best-in-class targeted strategy based on AHR activation or related pathway modulation to decrease pathological T cell populations in autoimmune conditions with a clearer mechanistic rationale than broad immune suppression.
      
      APPLICATIONS

      • Treatment of systemic autoimmune diseases driven by autoantibodies
      • Development of targeted AHR‑activating drugs or antibody–drug conjugates
      • CRISPR‑based or vector‑based interventions
      • Ex vivo modification of autologous T cells 

      
      ADVANTAGES

      • Defined disease mechanism 
      • Precision targeting
      • Rapid modulation

      
      PUBLICATIONS

      • Jaehyuk Choi et al., Interferon subverts an AHR–JUN axis to promote CXCL13+ T cells in lupus. Nature, 10 July 2024
      • Dimmer, O. Scientists Discover a Cause of Lupus and a Possible Way to Reverse It. Northwestern University Feinberg School of Medicine News Center. July 10, 2024

       

      ]]>Thu, 07 May 2026 15:53:44 GMTdragos@northwestern.eduhttps://www.canberra-ip.com/tech/Targeting_Autoimmunity-Associated_T_cells_via_AHR_Pathway_Control2023-127Thu, 07 May 2026 16:02:43 GMTAutoimmune disease, Immunology, Immunotherapy, Inflammation, RA - Rheumatoid arthritis, SLE - Systemic lupus erythematosus, Small molecule, Therapeutics, MichaelFiskeInvention ManagerMED-NUINmichael.fiske@northwestern.edu Therapeutics]]>Falsehttps://www.canberra-ip.com/tech?title=Antisense_oligonucleotides_to_prevent_genetic_mis-splicing_for_ALS%2fFTD_therapeuticsSHORT DESCRIPTION

      Antisense oligonucleotides (ASOs) that correct TDP‑43–dependent mis‑splicing of KCNQ2 thereby reducing neuronal hyperexcitability in ALS/FTD and related TDP‑43 proteinopathies.

      INVENTORS
      • Evangelos Kiskinis*
        • Northwestern University Feinberg School of Medicine, Department of Neurology
      • Jonathan Watts
      • Wanhao Chi

      * Principal Investigator

      NU Tech ID: NU 2023-020

      IP STATUS

      US Patent pending

      DEVELOPMENT STAGE

      TRL-3 Experimental Proof-of-Concept: Active R&D is underway with preliminary validation in cellular models.

      BACKGROUND

      Amyotrophic lateral sclerosis (ALS) is a rapidly fatal motor neuron disease with an incidence of roughly 2–3 per 100,000 person-years and a prevalence of about 7–9 per 100,000 in European and North American populations. Median survival from symptom onset is typically 2–4 years, and only a small minority of patients live beyond 10 years, making ALS one of the most devastating adult‑onset neurologic disorders. Frontotemporal dementia (FTD) is one of the most common causes of young-onset dementia, with pooled incidence estimates of roughly 2–4 per 100,000 and prevalence estimates of about 9–22 per 100,000. It causes profound behavioral, language, and executive dysfunction during working-age years. Currently available disease-modifying therapies for ALS do not directly tackle the root causes of neuronal hyperexcitability and provide only modest benefit, while the newer ASO therapy Tofersen is approved only for the small SOD1-mutant subset, leaving the >90% of ALS cases without a targeted therapy. Moreover, there are currently no approved disease‑modifying therapies for FTD and management is symptomatic, largely off‑label, and supported by relatively weak trial evidence. ALS and FTD are now understood as two ends of a shared TDP-43 proteinopathy spectrum, with TDP-43 pathology present in approximately 90% of ALS and about 50% of FTD cases. TDP-43 pathology leads to nuclear depletion and cytoplasmic aggregation, which in turn causes mis-splicing of key mRNAs. This dysregulation compromises ion channel function and contributes to disease progression and worsening patient development. There is therefore a clear unmet need for therapies that directly correct TDP‑43–driven splice defects in key ion channel genes to normalize excitability and potentially slow or prevent disease.

      ABSTRACT

      Northwestern researchers developed family of antisense oligonucleotides (ASOs), 10–30 nucleotides in length, designed to prevent TDP-43-dependent mis-splicing of KCNQ2, a key gene implicated in loss of functional ion channels, neuronal hyperexcitability, and earlier onset in ALS/FTD. This approach restores proper splicing in human iPSC-derived motor and cortical neurons subjected to TDP-43 depletion and patient tissue samples. The corrected splicing re-establishes functional Kv7.2 channels and reduces intrinsic hyperexcitability. The oligonucleotides use clinically validated chemistries, including phosphorothioate linkages and 2'-O-methoxyethyl modifications, and are positioned as a CNS-directed, splice-correcting therapeutic platform for ALS and FTD that complements the precedent established by approved ASO medicines in neurology. This strategy offers a promising therapeutic avenue for ALS/FTD by directly addressing a key molecular defect.

      APPLICATIONS

      • ASO therapy for ALS/FTD with TDP-43 pathology
      • Combination use with existing ALS agents or future TDP-43-directed therapies 
      • Diagnostic Biomarkers

      ADVANTAGES 

      • Mechanistically precise targeting
      • Restores proper ion channel function
      • Enhances neuronal stability
      • Broad addressable population

      PUBLICATIONS

      • Joseph BJ et al., TDP-43-dependent mis-splicing of KCNQ2 triggers intrinsic neuronal hyperexcitability in ALS/FTD. Nat Neurosci. Dec 2025.
      ]]>Thu, 07 May 2026 15:05:55 GMTdragos@northwestern.eduhttps://www.canberra-ip.com/tech?title=Antisense_oligonucleotides_to_prevent_genetic_mis-splicing_for_ALS%2fFTD_therapeutics2023-020Thu, 07 May 2026 16:11:14 GMTALS - Amyotrophic Lateral Sclerosis, FTD - Frontotemporal Dementia, Neurodegenerative disease, Neurologic disease, Neurology, Nucleic Acids, Rare diseases, Targeted therapy, Therapeutics, MichaelFiskeInvention ManagerMED-NUINmichael.fiske@northwestern.edu Therapeutics]]>Falsehttps://www.canberra-ip.com/tech/Incomplete_Autophagy_Induction_for_the_Treatment_of_CancerSHORT DESCRIPTION
      This incomplete autophagy inducer triggers caspase-mediated apoptosis in cancer cells by inducing incomplete autophagy, leading to tumor reduction and improved survival.

      INVENTORS

      INVENTORS
      • Maciej Lesniak*
        • Northwestern University Feinberg School of Medicine, Department of Neurological Surgery
      • Jawad Fares
      * Principal Investigator

      NU Tech ID: NU 2021-245

      IP STATUS

      US Patent pending.

      DEVELOPMENT STAGE

      TRL-5 Prototype Validated in Relevant Environment: Efficacy confirmed in multiple preclinical models demonstrating tumor reduction and enhanced survival.

      BACKGROUND
      Brain metastases are the most common central nervous system malignancy, occurring in an estimated 10–30% of adults with cancer and accounting for the majority of intracranial tumors. They often manifest with neurological impairment that portends poor quality of life and limits survival outcomes. Breast cancer is the most common cancer among women, impacting 2.1 million per year, and it is also the most common cause of cancer related deaths in women, with rates increasing in nearly every region globally. HER2‑positive and triple‑negative breast cancers have particularly high brain metastasis rates, and while novel targeted therapies have improved systemic control and survival in these aggressive forms of cancer, they are limited by high toxicity and poor blood–brain barrier penetration which leads to the emergence or or progression of CNS metastases despite effective extracranial disease control. There is an urgent need for innovative approaches that can more effectively target breast cancer brain metastases (BCBM) while minimizing side effects.

      ABSTRACT

      Northwestern researchers have developed a therapeutic strategy for cancer, especially breast, lung, melanoma, and primary brain tumors, based on incomplete autophagy induction to trigger caspase‑mediated apoptosis, with a particular focus on repurposing the CNS drug metixene (methixene) and related thioxanthene/piperidine small molecules. Instead of fully blocking or fully activating autophagy, the compounds drive an autophagic process that stalls before completion, leading to cellular stress, and apoptotic cell death in both primary and brain‑metastatic cancer cells while sparing normal tissue. The inventors describe methods of using such agents, including metixene, metixene HCl, and metixene hydrates, via systemic or local delivery and demonstrated significant decreases in cell viability and increased caspase activity in metastatic breast cancer models. In vivo, metixene reduces tumor size and extends survival in preclinical models of both primary breast cancer and brain metastases. The approach leverages modulation of autophagy pathways to induce apoptosis and offers a new avenue for cancer treatment.

      APPLICATIONS

      • Treatment of breast cancer brain metastases (BCBM)
      • Treatment of brain metastases
      • Breast cancer therapy
      • Treatment of primary brain tumors and other CNS malignancies
      • Combination therapy

      ADVANTAGES

      • Mechanistic novelty
      • Brain penetrant molecule
      • Reduces tumor size and improves survival in mouse models

      PUBLICATIONS

      • Maciej Lesniak et al, Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases, J Clin Invest, Dec 15, 2023
      ]]>Thu, 07 May 2026 14:58:13 GMTdragos@northwestern.eduhttps://www.canberra-ip.com/tech/Incomplete_Autophagy_Induction_for_the_Treatment_of_Cancer2021-245Thu, 07 May 2026 15:03:45 GMTBrain cancer, Breast cancer, Cancer/Oncology, Lung cancer, Melanoma, Repurposed Drugs, Small molecule, Therapeutics, MichaelFiskeInvention ManagerMED-NUINmichael.fiske@northwestern.edu Therapeutics]]>Falsehttps://www.canberra-ip.com/tech/Once-Weekly_Glucocorticoid_Steroid_Dosing_for_Enhanced_Muscle_Function_and_Metabolic_HealthSHORT DESCRIPTION

      A glucocorticoid regimen that preserves the benefits of steroids on muscle mass and function while mitigating many of the metabolic and growth‑related toxicities seen with daily dosing in various inflammatory, autoimmune, respiratory, and neuromuscular disease settings.

      INVENTORS
      • Elizabeth McNally*, MD, PhD
        • Northwestern University Feinberg School of Medicine, Department of Cardiology
      • Alexis Demonbreun
      • Mattia Quattrocelli
      * Principal Investigator

      NU Tech ID: 2018-192

      IP STATUS

      US Patent Pending (17/416,792)

      DEVELOPMENT STAGE

      TRL-5 Prototype Validated in Relevant Environment: Animal studies in multiple murine models have confirmed enhanced muscle performance and improved metabolic parameters.

      BACKGROUND

      Duchenne muscular dystrophy (DMD) is the most common childhood muscular dystrophy, affecting roughly 1 in 3,500–5,000 live male births worldwide and leading to progressive muscle weakness, loss of ambulation in early adolescence, cardiomyopathy, and premature mortality despite modern standards of care. Long‑term oral glucocorticoids are a cornerstone of DMD management because they improve strength, prolong ambulation, slow respiratory and cardiac decline, and reduce mortality. In fact, chronic systemic glucocorticoids are used across a broad range of inflammatory, autoimmune, respiratory, and neuromuscular diseases, including rheumatoid arthritis, severe asthma, COPD, lupus, inflammatory bowel disease (IBD), and DMD.  These conditions collectively affect tens to hundreds of millions of people worldwide, and it is estimated that ~0.5% of the general population receives long-term steroid therapy at any given time.  However, chronic daily dosing is known to cause muscle wasting, weakness, growth stunting, osteoporosis and fractures, obesity, and metabolic disorders which often limit adherence or force dose reduction or discontinuation. Clinical trials and meta‑analyses comparing daily versus intermittent regimens suggest that less‑frequent dosing can retain much of the functional benefit over 12–24 months while improving growth and bone outcomes, but the optimal schedule and underlying biology have remained unclear and practice patterns are heterogeneous.  Therefore, there is a significant unmet need for a safer, more effective dosing glucocorticoid strategy that maintains or enhances muscle efficacy and energy metabolism while minimizing systemic toxicity and other adverse side effects. 

      ABSTRACT

      Northwestern researchers have developed a method of using once‑weekly high‑dose glucocorticoid therapy, exemplified by weekly prednisone, to prevent and treat conditions of muscle wasting, aging, and metabolic disorder by engaging pro‑ergogenic transcriptional programs and nutrient‑sensing pathways while avoiding the catabolic transcriptional signature induced by daily steroids. The inventors demonstrate that adjusting glucocorticoid administration to a once-weekly regimen improves muscle mass, strength, and overall metabolic function in rodent models, whereas daily dosing produced a muscle‑atrophy and proteolysis gene signature.. The approach leverages multi-omic analyses to show enhanced utilization of amino acids, glucose, and fatty acids and increased levels of beneficial biomarkers like adiponectin. The method minimizes typical adverse effects seen in daily dosing, such as osteoporosis, and offers a new therapeutic avenue for preventing and treating muscle wasting, aging, and metabolic disorders without compromising efficacy.

      APPLICATIONS

      • Treatment or prevention of muscle wasting
      • Treatment or prevention of unhealthy aging
      • Treatment or prevention of metabolic disorders
      • Enhancement of exercise tolerance

      ADVANTAGES

      • Mechanistically optimized regimen
      • Improves both muscle performance and metabolic biomarkers for enhanced patient outcomes.
      • Simple dosing regimen with multiple dosing routes

      PUBLICATIONS

      • Quattrocelli M et al., Pulsed glucocorticoids enhance dystrophic muscle performance through epigenetic-metabolic reprogramming, JCI Insight. Dec 19, 2019
      • Quattrocelli M et al., Intermittent prednisone treatment in mice promotes exercise tolerance in obesity through adiponectin. J Exp Med. May 2, 2022.
      • Willis AB et al., Serum protein and imaging biomarkers after intermittent steroid treatment in muscular dystrophy. Sci Rep. Nov 20, 2024.
      ]]>Thu, 07 May 2026 14:47:16 GMTdragos@northwestern.eduhttps://www.canberra-ip.com/tech/Once-Weekly_Glucocorticoid_Steroid_Dosing_for_Enhanced_Muscle_Function_and_Metabolic_Health2018-192Mon, 11 May 2026 18:50:01 GMTAging, DMD - Duchenne muscular dystrophy, Immunology, Inflammation, Metabolic disorders, Muscle metabolism, Rare diseases, Small molecule, Therapeutics, MichaelFiskeInvention ManagerMED-NUINmichael.fiske@northwestern.edu Therapeutics]]>Falsehttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_Acumen_Pharmaceuticals%2c_Inc.
      

      Founded: 1996

      Northwestern Inventor:
      William Klein
      Weinberg College of Arts and Sciences
      Department of Neurobiology and Physiology

      Grant Krafft
      Feinberg School of Medicine
      Department of Molecular Pharmacology and Biological Chemistry

      Acumen Pharmaceuticals develops therapeutics for Alzheimer's Disease (AD) based upon the discovery and characterization of amyloid-derived diffusible ligands (ADDLs)

      Acumen Pharmaceuticals Website

      ]]>Thu, 07 May 2026 14:21:09 GMTdragos@northwestern.eduhttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_Acumen_Pharmaceuticals%2c_Inc.MKT-PROJ-26-0050Thu, 07 May 2026 14:29:19 GMTAntibody, Neurodegenerative disease, Neurologic disease, Therapeutics, StartupAvailable for Partnershipinvo@northwestern.edu Therapeutics| Life Sciences > Healthcare Devices, Tools & IT]]>Falsehttps://www.canberra-ip.com/tech/Novel_ZnO_Nanowire-Based_Hybrid_Nanocarrier_for_Cancer_Drug_and_Gene_DeliveryThis invention relates to a novel tri-component nanocomposite system comprising commercially available zinc oxide nanowires (ZnO NWs) functionalized to simultaneously deliver both small-molecule drugs and genetic material to cancer cells. This hybrid nanocarrier platform addresses critical limitations of current cancer therapies, including poor tumor selectivity, systemic toxicity, and inability to co-deliver multiple therapeutic modalities.
      
      Background: 
      Cancer remains the second leading cause of death worldwide, with over 10 million deaths annually, driven in part by therapeutic resistance, poor tumor penetration, and systemic toxicity of conventional chemotherapies. Systemic drug administration often leads to insufficient tumor accumulation and off-target toxicity in organs such as the liver and kidneys, limiting efficacy and increasing adverse effects. Improving tumor specificity and enabling combinatorial delivery of small-molecule drugs and genetic therapies is therefore critical for advancing more effective cancer treatments. Nanocarrier-based platforms that implement nanowires, such as this invention, have emerged in modern cancer nanomedicine as they are able to penetrate tumor cells more efficiently and deliver multiple treatments at the same time, which can increase tumor elimination while reducing side effects compared with conventional drug delivery methods.
      
      Applications: 
      • Nanotechnology for drug delivery
      • Cancer nanomedicine
      • Theranostics

      
      Advantages: 

      • Improved tumor selectivity and specificity
      • Reduced systemic toxicity
      • Applicable across multiple cancer types
      • Potential combination therapies due to dual-payload capability
      ]]>Wed, 06 May 2026 17:40:08 GMTJianlingL@tla.arizona.eduhttps://www.canberra-ip.com/tech/Novel_ZnO_Nanowire-Based_Hybrid_Nanocarrier_for_Cancer_Drug_and_Gene_DeliveryUA26-163Wed, 06 May 2026 17:40:08 GMTPrashantSharmapsharma1@arizona.eduMarioOttoProfessor, Division ChiefChild Healthmotto@phoenixchildrens.com35 31 31 32GarrettEdmundsLicensing Manager, UAHS-TLAgedmunds@arizona.edu Healthcare Portfolios > Oncology| Technology Classifications > Life Sciences > Diagnostics| Technology Classifications > Life Sciences > Drug Delivery| Technology Classifications > Life Sciences > Therapeutics]]>Falsehttps://www.canberra-ip.com/tech?title=ERG-7_Inhibitors%3a_Targeting_the_Sterol_Biosynthetic_PathwayThis invention relates to small molecule anti-fungal compounds, pharmaceutical compositions, and methods of use for the prevention, treatment, or mitigation of fungal diseases in human and veterinary subjects. In particular aspects, the invention provides inhibitors that modulate fungal sterol biosynthesis, including inhibitors of lanosterol synthase (ERG7). These can be used as a sole therapeutic or in combination with standard antifungals to improve efficacy.
      
      Background: 
      ERG7 inhibitors target the problem of rising antifungal resistance, particularly to azoles that act later in sterol biosynthesis. Unlike current therapies, such as azoles, echinocandins, polyenes, etc., that suffer from resistance, toxicity, or fungistatic effects, ERG7 inhibitors block an upstream, essential sterol step, causing fungicidal activity and reduced cross-resistance, though achieving fungal selectivity remains a key challenge.
      
      Applications: 
      • Small molecule inhibitor
      • Antifungal therapeutic
      • Combination antifungal therapy
      • Human & veterinary fungal prevention, treatment, and mitigation 

      
      Advantages: 

      • Selectivity between fungal ERG7 and human lanosterol synthase
      • Can be used in combination with standard antifungals
      • Addresses resistance to standard antifungals (azole-resistant fungi)
      • Attacks fungal cell membrane formation
      • Broad medication administration methods
      • Reduce fungal related healthcare costs 
      • Expand available fungal prevention, treatment, and mitigation medications
      ]]>Wed, 06 May 2026 17:28:57 GMTJianlingL@tla.arizona.eduhttps://www.canberra-ip.com/tech?title=ERG-7_Inhibitors%3a_Targeting_the_Sterol_Biosynthetic_PathwayUA26-037Wed, 06 May 2026 17:28:57 GMTRuiXiongAssist Professorrxiong@pharmacy.arizona.eduHongminLiProfessorPharmacology and Toxicologyhli1@pharmacy.arizona.edu518-473-5217Malla ReddyGannarapuPostdocPharma Toxmallareddy@arizona.eduDivakarIndukuriPost DocPharmacology and Toxicologydivakarindukuri@gmail.comAnilTharappelResearcher/Scientist IIIPharmacology and Toxicologyaniltharappel@arizona.eduKeChenPhD studentkechen2@arizona.eduMengjiaoMaPhD studentmengjiaoma@arizona.eduGarrettEdmundsLicensing Manager, UAHS-TLAgedmunds@arizona.edu Healthcare Portfolios > Infectious Diseases| Technology Classifications > Healthcare Portfolios > Neurology| Technology Classifications > Healthcare Portfolios > Respiratory & Pulmonary| Technology Classifications > Life Sciences > Small Molecules| Technology Classifications > Life Sciences > Therapeutics]]>Falsehttps://www.canberra-ip.com/tech/Multi-Targeted_Kinase_Inhibitors_Towards_AML_and_Other_CancersThis invention relates to small-molecule compounds that are potential therapeutics for Acute Myeloid Leukemia (AML), specifically AML with the FMS-like tyrosine kinase 3 (FLT3) mutation. The compounds also show activity versus Abl kinases, platelet-derived growth factor receptor (PDGFR), and the dual-specificity tyrosine regulated/Cdc2-like (DYRK/CLK) family of kinases, well-known targets for anti-cancer therapeutics. These compounds could be used in conjunction with the current AML therapeutic standard of care Gilteritinib, or as a standalone therapeutic, especially for patients that have developed resistance to Gilteritinib. 
      
      Background: 
      Acute myeloid leukemia (AML) is a type of cancer that affects the blood and begins in the bone marrow, rapidly spreading into the bloodstream. It can sometimes extend to other areas of the body, such as the lymph nodes, liver, spleen, brain, spinal cord, and testicles. Among AML subtypes, FLT3 mutations are among the most frequent genetic alterations, occurring in about 25–35% of adult AML cases. These mutations confer an adverse prognosis, including higher relapse rates and shorter overall survival. Gilteritinib is the most widely used therapy for relapsed/refractory FLT3-mutated AML, but patients can develop drug resistance through mechanisms such as new FLT3 gene mutations or bypassing signaling pathways. This invention can be a potential second-line treatment to Gilteritinib for AML, for patients who have developed resistance to the Gilteritinib.
      
      Applications: 
      • Acute Myeloid Leukemia (AML) therapeutics
      • Kinase inhibitors
      • Personalized cancer treatment

      
      Advantages: 

      • Multi-targeted kinase inhibitor
      • Combats Gilteritinib resistance
      • Broader therapeutic potential
      ]]>Wed, 06 May 2026 17:25:26 GMTJianlingL@tla.arizona.eduhttps://www.canberra-ip.com/tech/Multi-Targeted_Kinase_Inhibitors_Towards_AML_and_Other_CancersUA26-010Wed, 06 May 2026 17:25:26 GMTChristopherHulmeProfessorPharmacology and Toxicologyhulme@arizona.edu520-626-5322AlessandraFistrovichGraduate StudentChemistryahf@email.arizona.eduSamanthaRokeyGraduate StudentCBCsammirokey@gmail.comAidanMcMahonGrad StudentCBCaidanmcmahon@arizona.eduTimothyChavezGraduate StudentChemistry and Biochemistrychaveztim98@gmail.comJenniferCarewAssociate ProfessorMedicinejcarew@email.arizona.eduGarrettEdmundsLicensing Manager, UAHS-TLAgedmunds@arizona.edu Healthcare Portfolios > Oncology| Technology Classifications > Life Sciences > Small Molecules| Technology Classifications > Life Sciences > Therapeutics]]>Falsehttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_NanoAl_(Acquired_by_Braidy_Industries)
      

      Founded: 2013

      Northwestern Inventor:
      David C. Dunand
      McCormick School of Engineering and Applied Sciences
      Department of Materials Science and Engineering
      Faculty Profile

      David N. Seidman
      McCormick School of Engineering and Applied Sciences
      Department of Materials Science and Engineering
      Faculty Profile

      NanoAl, LLC, is a technology company dedicated to the design and development of high performance aluminum alloys. NanoAl alloys can be processed by conventional (casting) and non-conventional (powder metallurgy) methods, and have a wide range of application in the automotive, power transmission, and other industries.

      NanoAl (Acquired by Braidy Industries) Website

      ]]>Tue, 05 May 2026 20:55:25 GMTdragos@northwestern.eduhttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_NanoAl_(Acquired_by_Braidy_Industries)MKT-PROJ-26-0120Tue, 05 May 2026 20:55:25 GMTMetals, Startup with Northwestern IP, StartupAvailable for Partnershipinvo@northwestern.edu Materials and Industrial Processes]]>Falsehttps://www.canberra-ip.com/tech?title=A_Fungal%e2%80%93Nanoparticle_Delivery_Platform_for_Targeted_Therapeutic_Transport_Across_the_Blood%e2%80%93Brain_BarrierImmune-Evasive Fungal Carriers for Targeted, Noninvasive Central Nervous System Drug Delivery

      This fungal–nanoparticle drug delivery platform uses Cryptococcus neoformans (CN) for effective drug delivery to the central nervous system (CNS). More than 1.2 billion people worldwide are affected by neurological disorders, yet fewer than 2% of approved therapeutics successfully enter the central nervous system (CNS) for meaningful therapeutic effects. Evidently, there is a significant unmet need for drug delivery to the CNS to counteract a plethora of maladies including neurodegenerative diseases (e.g., amyotrophic lateral sclerosis; ALS), brain cancers (e.g., Gliobastoma Multiforme; GBM), traumatic nervous system injury, and epilepsy.

       

      Lou Gehrig’s disease (ALS) affects over 200,000 individuals globally and remains a fatal neurodegenerative condition with only marginally effective treatment options. Current ALS therapies are limited to small-molecule drugs that rely on passive diffusion to enter the CNS. Despite their ability to cross the blood-brain barrier (BBB), these agents suffer from poor CNS bioavailability due to rapid systemic distribution and off-target accumulation, resulting in modest clinical benefit and dose-limiting side effects. Additional challenges include the blood–spinal cord barrier and physicochemical properties (e.g., solubility, molecular weight, stability, etc.) that restrict drug accumulation at sites of motor neuron degeneration.

       

      Glioblastoma (GBM) remains one of the most urgent and unmet needs in oncology. As the most aggressive primary brain tumor in adults, GBM is characterized by rapid growth, diffuse infiltration into surrounding brain tissue, and profound resistance to existing therapies. Despite decades of research, the standard of care—maximal surgical resection followed by radiation and chemotherapy with Temozolomide—offers only modest benefit, with median overall survival typically limited to 12–15 months and a five-year survival rate below 10%. The therapeutic challenge in GBM is driven by several factors: marked tumor heterogeneity, an immunosuppressive tumor microenvironment, and the protective Blood–brain barrier, which restricts effective drug delivery. In addition, GBM’s infiltrative nature prevents complete surgical removal and contributes to nearly universal recurrence. There is a critical need for innovative therapeutic strategies that go beyond cytotoxic approaches. Emerging modalities—including targeted therapies, immune-based treatments, gene and cell therapies, and advanced drug delivery systems—aim to overcome these barriers, improve tumor specificity, and generate durable responses. However, clinical success has been limited to date, underscoring the urgency for continued investment in novel mechanisms and translational research.

       

      Researchers at the University of Florida have developed a fungal drug carrier platform for enhancing blood-brain barrier penetration and reducing off-target distribution. The platform exploits the natural immune evasiveness and CNS trafficking properties of an avirulent strain of Cryptococcus neoformans. The fungal carrier is surface-modified with drug-loaded nanoparticles, enabling immune-cell–mediated transport across the BBB and targeted delivery to the brain and spinal cord. The approach can significantly improve therapeutic efficacy, reduce dosing requirements, and minimize side effects. While initially developed for ALS, this platform is broadly applicable to a range of neurological and neurodegenerative disorders where effective CNS drug delivery remains a critical unmet need.

       

      Application

      This fungal–nanoparticle delivery platform enables targeted transport of therapeutics across the blood–brain and blood–spinal cord barriers to improve CNS drug bioavailability and efficacy while minimizing off-target effects for the treatment of ALS and other neurological disorders

       

      Advantages

      • Leverages a naturally evolved BBB-crossing mechanism, enabling efficient, noninvasive transport of therapeutics into the CNS
      • Avoids invasive CNS delivery methods, reducing patient risk, procedural complexity, and clinical cost compared to intrathecal or intracerebral administration
      • Enables targeted and sustained drug release in the brain, increasing local therapeutic concentrations at disease sites while minimizing systemic exposure and off-target side effects

       

      Technology

      A fungal–nanoparticle drug delivery platform uses an avirulent strain of Cryptococcus neoformans to enable noninvasive transport of therapeutics across the blood–brain and blood–spinal cord barriers. Drug-loaded, FDA-approved nanoparticles are surface-conjugated to the fungal carrier, preserving payload stability while leveraging the organism’s naturally evolved immune-evasive and CNS-trafficking properties. Following systemic administration, the platform exploits immune-cell–mediated transport to cross CNS barriers and localize within brain and spinal cord tissues. Once in the CNS, the nanoparticles provide controlled and sustained drug release, increasing local therapeutic concentrations while minimizing systemic exposure and off-target effects. The modular design allows tuning of nanoparticle composition, drug payload, and release kinetics, enabling adaptation to multiple therapeutic agents and neurological indications while avoiding invasive CNS delivery methods.

      ]]>Tue, 05 May 2026 20:40:36 GMTsaradagen@ufl.eduhttps://www.canberra-ip.com/tech?title=A_Fungal%e2%80%93Nanoparticle_Delivery_Platform_for_Targeted_Therapeutic_Transport_Across_the_Blood%e2%80%93Brain_BarrierMP26035Tue, 05 May 2026 20:46:53 GMTJamalLewisFacultyEG-BIOMEDICAL ENGINEERINGjamalslewis@ufl.eduClintonSmith, IVNSF Graduate Research FellowBiomedical Engineeringsmith.clinton@ufl.eduNoahPacificinoah.pacifici@gmail.comRachelHardingAssistant DirectorOR-TECHNOLOGY LICENSINGrharding@ufl.edu Human Health Care > Drug Delivery]]>Falsehttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_NanoIntegris%2c_Inc._(Acquired_by_Raymor_Industries)
      

      Founded: 2006

      Northwestern Inventor:
      Mark Hersam
      McCormick School of Engineering and Applied Science
      Department of Material Science and Engineering
      Faculty Profile

      NanoIntegris is a leading supplier of premium single- and double-walled carbon nanotubes (SWNT, DWNT). The technology separates nano-tubes by diameter and/or electronic type (i.e., metal vs. semiconductor). These ultrapure materials enable commercial electronic, semiconductor, and display applications.

      NanoIntegris (Acquired by Raymor Industries) Website

      ]]>Tue, 05 May 2026 20:40:24 GMTdragos@northwestern.eduhttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_NanoIntegris%2c_Inc._(Acquired_by_Raymor_Industries)MKT-PROJ-26-0122Tue, 05 May 2026 20:44:27 GMTStartupAvailable for Partnershipinvo@northwestern.edu Materials and Industrial Processes]]>Falsehttps://www.canberra-ip.com/tech?title=Strategy_For_Precise%2c_Robust%2c_And_Advanced_Analysis_Of_Carbon_In_Urban_EcosystemsAn analytical method and software workflow for quantitatively separating and measuring different carbon forms in urban soils.
      Problem:
      Organic carbon (OC) is derived from biomass. Black carbon (BC) is a product of the thermal decomposition of OC. Inorganic carbon (IC) exists in nonbiological matter, such as carbon dioxide and carbonates. Urban soils typically contain complex mixtures of all three, but BC and IC are difficult to differentiate from OC. Although accurate characterization of the global carbon cycle is essential for sustainable urban development, there is currently no standardized method to quantify these carbon forms. Conventional methods have been time-consuming, expensive, dangerous, and/or unreliable, in part due to the complexity and temperature-dependence of urban soil composition.
      Solution:
      Evolved gas analysis (EGA), in which researchers measure the carbon dioxide released during ramped combustion, presents a pathway for directly quantifying carbon. When applied to model mixtures of urban soils, this method outperformed the widely used thermogravimetric analysis (TGA).
      Technology:
      EGA quantifies carbon by measuring the evolved carbon dioxide, isolating individual thermal peaks, and assigning each peak to the appropriate carbon form using sample-specific local minimums. Unlike TGA, in which the soil sample is measured as a function of temperature, EGA can accommodate samples with disproportionate carbon losses, dehydration and overlapping thermal thresholds.
      Advantages:
      
      • Identifies OC, BC, and IC from overlapping thermal signals
      • Requires no acid pretreatment
      • Outperforms TGA-based methods

      Stage of Development:
      

      • Concept
      • Proof of Concept

      
      
      
      The evolved gas analysis thermograms obtained during ramped combustion. Panel (a) shows the carbon dioxide released at the given temperatures for the reference materials glucose, cellulose, lignin, Diesel soot, and calcium carbonate. Panel (b) shows that of the example carbon dioxide thermogram for a model mixture. The model mixtures contained known amounts of organic carbon, black carbon, and inorganic carbon within a mix of montmorillonite, a natural clay mineral. Panel (c) presents the peak deconvolution result for the model mixture, wherein the overlapping signals are separated by carbon source.
      Intellectual Property:
      

      • Non-US Application Pending

      Reference Media:
      

      • Hyun, J. et. al., Eur. J. Soil Sci., 2025 April 15; Vol. 76, Issue 2: e70107 

      Desired Partnerships:
      

      • License
      • Co-Development

      Docket #26-11375
       

      ]]>Tue, 05 May 2026 20:23:32 GMTlbricha@upenn.eduhttps://www.canberra-ip.com/tech?title=Strategy_For_Precise%2c_Robust%2c_And_Advanced_Analysis_Of_Carbon_In_Urban_Ecosystems26-11375_tpNCSTue, 05 May 2026 20:35:16 GMTAn analytical method and software workflow for quantitatively separating and measuring different carbon forms in urban soils.Problem:Organic carbon (OC) is derived from biomass. Black carbon (BC) is a product of the thermal decomposition of OC. Inorganic carbon (IC) exists in nonbiological matter, such as carbon dioxide and carbonates. Urban soils typically contain complex mixtures of all three, but BC and IC are difficult to differentiate from OC. Although accurate characterization of the global carbon cycle is essential for sustainable urban development, there is currently no standardized method to quantify these carbon forms. Conventional methods have been time-consuming, expensive, dangerous, and/or unreliable, in part due to the complexity and temperature-dependence of urban soil composition.Solution:Evolved gas analysis (EGA), in which researchers measure the carbon dioxide released during ramped combustion, presents a pathway for directly quantifying carbon. When applied to model mixtures of urban soils, this method outperformed the widely used thermogravimetric analysis (TGA).Technology:EGA quantifies carbon by measuring the evolved carbon dioxide, isolating individual thermal peaks, and assigning each peak to the appropriate carbon form using sample-specific local minimums. Unlike TGA, in which the soil sample is measured as a function of temperature, EGA can accommodate samples with disproportionate carbon losses, dehydration and overlapping thermal thresholds.Advantages:
      • Identifies OC, BC, and IC from overlapping thermal signals
      • Requires no acid pretreatment
      • Outperforms TGA-based methods]]>Stage of Development:
        • Concept
        • Proof of Concept]]>
          ]]>The evolved gas analysis thermograms obtained during ramped combustion. Panel (a) shows the carbon dioxide released at the given temperatures for the reference materials glucose, cellulose, lignin, Diesel soot, and calcium carbonate. Panel (b) shows that of the example carbon dioxide thermogram for a model mixture. The model mixtures contained known amounts of organic carbon, black carbon, and inorganic carbon within a mix of montmorillonite, a natural clay mineral. Panel (c) presents the peak deconvolution result for the model mixture, wherein the overlapping signals are separated by carbon source.Intellectual Property:
          • Non-US Application Pending]]>Reference Media:
            • Hyun, J. et. al., Eur. J. Soil Sci., 2025 April 15; Vol. 76, Issue 2: e70107 ]]>Desired Partnerships:
              • License
              • Co-Development]]>Docket #26-11375AlainPlanteProfessoraplante@sas.upenn.edu215-898-9269JungeHyunGayoungYooGangotriDeyLicensing Officer, SEAS/SAS Licensing GroupPenn Center for Innovationgdey6@upenn.edu Agriculture & Environment| Technology Classifications > Research Tools & Reagents| Technology Classifications > Testing & Measurement]]>Falsehttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_NuMat_Technologies%2c_Inc
                

                Founded: 2011

                Northwestern Inventor:
                Omar Farha
                Weinberg School of Arts & Sciences
                Department of Chemistry
                View Faculty Profile

                Randall Q. Snurr
                McCormick School of Engineering and Applied Science
                Department of Chemical and Biological Engineering

                Joseph T. Hupp
                Weinberg College of Arts and Sciences
                Department of Chemistry
                View Faculty Profile

                Numat Technologies is an advanced materials company that computationally designs and synthesizes nanoporous materials for gas storage and separation applications. It is a market leader in Metal-Organic Frameworks (”MOFs”), a transformative precision chemistry platform. MOFs can be designed, atom-by-atom, to capture and separate target hazardous chemicals in ways limited by traditional methods.

                Through their integrated platform, they design, scale and deliver powerful solutions into their customers’ products and processes, reducing the negative impact of chemical products and processes on human health and the environment. 

                Numat Technologies Website

                ]]>Tue, 05 May 2026 20:21:02 GMTdragos@northwestern.eduhttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_NuMat_Technologies%2c_IncMKT-PROJ-26-0128Tue, 05 May 2026 20:31:33 GMTCatalyst, Energy and Infrastructure, Environment, Materials, MOFs, Polymer, Startup with Northwestern IP, StartupAvailable for Partnershipinvo@northwestern.edu Energy & Sustainability| Physical Sciences > Materials and Industrial Processes]]>Falsehttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_Volexion%2c_Inc.
                

                Founded: 2018

                Northwestern Inventor:
                Mark Hersam
                McCormick School of Engineering & Applied Sciences
                Materials Science
                Faculty Profile

                Volexion is developing advanced cathode materials for lithium ion batteries that overcome key limitations to conventional technology, primarily enhanced battery performance at low temperatures and rapid charging and discharging. Their cathode material provides high energy efficiency, improves cycling stability and utilizes safer materials.

                 

                 

                Volexion Website

                ]]>Tue, 05 May 2026 20:07:35 GMTdragos@northwestern.eduhttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_Volexion%2c_Inc.MKT-PROJ-26-0163Tue, 05 May 2026 20:41:17 GMTBatteries, Energy and Infrastructure, Energy storage, Graphene, Lithium-ion, Materials, Startup with Northwestern IP, StartupAvailable for Partnershipinvo@northwestern.edu Energy & Sustainability| Physical Sciences > Materials and Industrial Processes]]>Falsehttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_NanoGraf
                

                Founded: 2012

                Northwestern Inventor:
                Harold Kung
                McCormick School of Engineering and Applied Science
                Department of Chemical and Biological Engineering

                Jiaxing Huang
                McCormick School of Engineering and Applied Science
                Department of Materials Science

                Formerly SiNode Systems, NanoGraf pursues advances in Lithium-ion battery anodes to transform a wide range of industries from consumer electronics to electric vehicles. NanoGraf’s anode technology utilizes a composite of silicon nano-particles within a patent-pending graphene scaffolding system that increases a battery's energy density (5-7 times) and reduces the charging time of a lithium-ion battery up to a factor of 10.

                 

                NanoGraf Website

                ]]>Tue, 05 May 2026 19:43:18 GMTdragos@northwestern.eduhttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_NanoGrafMKT-PROJ-26-0121Tue, 05 May 2026 19:43:18 GMTBatteries, Energy and Infrastructure, Fuel Cell, Graphene, Nanoparticle, Startup with Northwestern IP, Sustainability, Sustainable Materials, StartupAvailable for Partnershipinvo@northwestern.edu Energy & Sustainability| Physical Sciences > Materials and Industrial Processes]]>Falsehttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_Lilac_Solutions
                

                Founded: 2016

                Northwestern Inventor:
                Christopher Wolverton
                McCormick School of Engineering and Applied Science
                Department of Materials Science and Engineering

                Lilac Solutions is developing new ion exchange materials to transform lithium extraction from brine resources.

                Lilac Solutions Website

                ]]>Tue, 05 May 2026 19:32:12 GMTdragos@northwestern.eduhttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_Lilac_SolutionsMKT-PROJ-26-0111Tue, 05 May 2026 19:40:06 GMTBatteries, Energy and Infrastructure, Manufacturing/Processing, Materials, Startup with Northwestern IP, Sustainability, Sustainable Materials, StartupAvailable for Partnershipinvo@northwestern.edu Energy & Sustainability]]>Falsehttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_Syenex%2c_Inc.
                

                Northwestern Inventor:
                Joshua Leonard
                McCormick School of Engineering
                Chemical and Biological Engineering

                Syenex builds bioengineering technologies to unlock the future of human health. Leveraging the power of synthetic biology, we design scalable, precision-engineered components, empowering cell and gene therapy developers to cure disease and build the next generation of medicines. Designed to break the barriers that slow medical progress, our Open Science model ensures global access to our expanding toolkit and network of scale-up partners, accelerating the path of breakthroughs from idea to impact for all of academia and biopharma. Since 2022, Syenex has rapidly built a portfolio of cell-specific bioengineering system and established partnerships across the fields of immune cell, stem cell, and hepatocyte engineering.

                ]]>Tue, 05 May 2026 19:05:54 GMTdragos@northwestern.eduhttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_Syenex%2c_Inc.MKT-PROJ-26-0150Tue, 05 May 2026 19:54:37 GMTBiologic, Biomedical, Drug delivery, Gene therapy, Platform technology, Research tool, Startup with Northwestern IP, Synthetic biology, Therapeutics, Vector/Plasmid, StartupAvailable for Partnershipinvo@northwestern.edu Biomarkers & Biomedical Research Tools| Life Sciences > Therapeutics]]>Falsehttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_Yobee_Care%2c_Inc.
                

                Founded: 2018

                Northwestern Inventor:
                Dr. Ruchi Gupta
                Feinberg School of Medicine
                Department of Pediatrics and Medicine

                Yobee's mission is to revolutionize scalp, hair, and skin care by helping consumers rebalance their microbiome and eliminating the need for chemical-laden products. Utilizing PROBYOME , our patented blend of probiotic extracts, organic honey, organic turmeric, and Vitamin B12, Yobee aims to improve health and support a balanced microbiome for a lifetime of healthy hair and skin. Yobee products are made in the USA with clean, carefully sourced ingredients, providing families with safe, scientifically backed solutions for various scalp and skin issues.

                Yobee Care Website

                ]]>Tue, 05 May 2026 18:58:30 GMTdragos@northwestern.eduhttps://www.canberra-ip.com/tech?title=Northwestern_Startup%3a_Yobee_Care%2c_Inc.MKT-PROJ-26-0165Tue, 05 May 2026 20:00:03 GMTDermatology, Hair care, Scalp care, Skin care, Startup with Northwestern IP, Therapeutics, StartupAvailable for Partnershipinvo@northwestern.edu Therapeutics]]>Falsehttps://www.canberra-ip.com/tech?title=An_All-In-One_%e2%80%9cSwiss_Army_Knife%e2%80%9d_Tool_To_Edit_Genes_And_Regulate_Their_Expression_Without_Off-Target_Effects_And_ToxicityA flexible toolkit for human gene editing, activation, and repression that can be applied in orthogonally and in various disease models.
                Problem:
                There is increasing demand for technologies that can simultaneously edit the genome and regulate the transcriptome without relying on toxic double-stranded breaks. Currently, treating complex diseases such as cancer require correcting genomic point mutations while simultaneously activating or repressing secondary genes that are deregulated. These independent tasks require the co-delivery of multiple large effectors, drastically exceeding the strict packaging limits of modern clinical vectors like AAVs. Therefore, there is a dire need for a single, compact tool that provides orthogonal control over gene editing and expression. Such a unified platform would bypass viral packaging bottlenecks, eliminate CRISPR/Cas9-induced cytotoxicity, and unlock next-generation precision therapies.
                Solution:
                This invention is a minimal versatile genetic perturbation technology (mvGPT), which combines a prime editor (PE), fusion activator (MPH), and a multiplex array that produces RNA tailored for a variety of genetic perturbations, including genomic editing, gene activation, and gene repression. Importantly, unlike other currently available tools, mvGPT can be used orthogonally – such that gene activation, repression, and editing can be deployed independently and without interference among functions.
                Technology:
                The invention consists of three main components: an engineered compact prime editor (Prime Editor with Advanced Kernel, or PEAK), a transcriptional activator (MS2–p65–HSF1, or MPH), and an RNA system that produces short RNAs to direct editing, activation, or silencing of specific genes (drive-and-process array, or DAP). DAP, in combination with prime editing guide RNA (pegRNA) and nicking guide RNA (ngRNA), efficiently guides PEAK to target loci to modify DNA. MPH and PEAK are guided by short guide RNA to activate gene transcription. Finally, DAP encodes short hairpin RNA and facilitates gene repression through RNA interference.
                Advantages:
                
                • Orthogonal and independent deployment of gene editing, activation, and repression without interference
                • Versatile delivery approaches of the mvGPT components (AAV, LV, mRNA, plasmids)
                • Compatible with human cells and human disease models
                • Does not result in DSB of DNA or cytotoxicity associated with existing gene editing methods
                • Proof-of-concept model results in simultaneous 5% correction for the disease-causing gene ATP7B, a 1700-fold activation of the PDX1 gene, and a 93% repression of the TTR gene in a human cell line
                • Can be utilized for any application requiring gene editing, activation, and/or repression

                Stage of Development:
                

                • Proof of Concept

                
                
                
                Simultaneous editing, activation, and silencing of disease-relevant genes using mvGPT in human liver cells. (A) Structure of the DAP RNA array encoding for nicking guide RNA (ngRNA) and engineered prime editing guide RNA (epegRNA) for gene editing, a truncated activation single guide RNA (agRNA) for gene activation, and a short hairpin RNA (shRNA) for gene silencing. (B) Schematic of a genetic disease model requiring orthogonal editing, activation, and silencing of a set of genes. This example exhibits a model involving Wilson’s disease, Type I diabetes, and Transthyretin amyloidosis. Rows indicate the disease, gene of interest, and the perturbation involved. (C) Illustration of HepG2 cells line (human liver cancer cells) transfected by plasmids encoding the three main elements of the mvGPT: prime editing system with advanced kernel (PEAK), fusion activator MS2–p65–HSF1 (MPH), and the drive-and-process (DAP) multiplexed RNA expression array. (D) mvGPT successfully corrected the ATP7B mutation in 5% of treated cells, increased PDX1 gene expression up to 1,700-fold, and reduced TTR gene expression by 93% -- all   at once. FWD and REV indicate two versions of the DAP array with RNA components encoded in opposite order, both yielding comparable results.
                Intellectual Property:
                

                • PCT Pending

                Reference Media:
                

                • Yuan, Q. et. al., Nat Commun., 2024 Dec 30; 15 (1):10868
                • Dr. Xue Sherry Gao Research Page 

                Desired Partnerships:
                

                • License
                • Co-Development

                Docket #26-11294

                 

                 

                 

                ]]>Tue, 05 May 2026 18:06:20 GMTlbricha@upenn.eduhttps://www.canberra-ip.com/tech?title=An_All-In-One_%e2%80%9cSwiss_Army_Knife%e2%80%9d_Tool_To_Edit_Genes_And_Regulate_Their_Expression_Without_Off-Target_Effects_And_Toxicity26-11294-tpNCSTue, 05 May 2026 18:06:20 GMTA flexible toolkit for human gene editing, activation, and repression that can be applied in orthogonally and in various disease models.Problem:There is increasing demand for technologies that can simultaneously edit the genome and regulate the transcriptome without relying on toxic double-stranded breaks. Currently, treating complex diseases such as cancer require correcting genomic point mutations while simultaneously activating or repressing secondary genes that are deregulated. These independent tasks require the co-delivery of multiple large effectors, drastically exceeding the strict packaging limits of modern clinical vectors like AAVs. Therefore, there is a dire need for a single, compact tool that provides orthogonal control over gene editing and expression. Such a unified platform would bypass viral packaging bottlenecks, eliminate CRISPR/Cas9-induced cytotoxicity, and unlock next-generation precision therapies.Solution:Technology:Advantages:
                • Orthogonal and independent deployment of gene editing, activation, and repression without interference
                • Versatile delivery approaches of the mvGPT components (AAV, LV, mRNA, plasmids)
                • Compatible with human cells and human disease models
                • Does not result in DSB of DNA or cytotoxicity associated with existing gene editing methods
                • Proof-of-concept model results in simultaneous 5% correction for the disease-causing gene ATP7B, a 1700-fold activation of the PDX1 gene, and a 93% repression of the TTR gene in a human cell line
                • Can be utilized for any application requiring gene editing, activation, and/or repression]]>Stage of Development:
                  • Proof of Concept]]>
                    ]]>Intellectual Property:
                    • PCT Pending]]>Reference Media:
                      • Yuan, Q. et. al., Nat Commun., 2024 Dec 30; 15 (1):10868
                      • Dr. Xue Sherry Gao Research Page ]]>Desired Partnerships:
                        • License
                        • Co-Development]]>Docket #26-11294Xue SherryGaoAssociate ProfessorSEAS-Chemical and Biomolecular Engineeringxuegao@seas.upenn.eduTylerDanielCBE Research FellowSEAS-Chemical and Biomolecular Engineeringtydaniel@seas.upenn.eduHongzhiZengQichenYuanBioengineering, Cell Therapy, Gene Editing, Genetic Disorders, Neurodegenerative Diseases, Obesity Metabolic Disease and Diabetes, Oncology, Orphan Disease, Pulmonary, GangotriDeyLicensing Officer, SEAS/SAS Licensing GroupPenn Center for Innovationgdey6@upenn.edu Research Tools & Reagents| Technology Classifications > Therapeutics]]>Falsehttps://www.canberra-ip.com/tech?title=Fast%2c_Background-free_Detection_of_Nucleic_Acid_Sequences_Using_DNA_NanoswitchesThis technology introduces DNA-based "nanoswitches"—innovative nanostructures that enable precise and efficient detection of target analytes through conformational changes. 

                          Background:
                          Accurate detection of specific molecules, such as DNA sequences or other analytes, is fundamental in medical diagnostics, environmental monitoring, and biochemical research. Traditional detection methods often face challenges such as limited sensitivity, high cost, or slow processing times. To address these issues, researchers developed DNA nanostructures capable of responding to target molecules with measurable changes, aiming to create a detection system that is both highly specific and efficient.

                          Technology Overview:  
                          The core innovation involves "nanoswitches," which are specially engineered DNA nanostructures formed from single-stranded oligonucleotides. These nanoswitches switch between looped (on) and unlooped (off) states depending on the presence of specific target molecules. When a target analyte binds to the nanoswitch, it induces a conformational shift that can be detected through established laboratory techniques such as gel electrophoresis, nanopore analysis, or fluorescence analysis. What sets this technology apart is its ability to precisely detect a wide variety of analytes with exceptional sensitivity and specificity. The conformational change acts as a clear molecular signal indicating the presence or absence of the target. Moreover, the design allows for multiplexed detection—meaning multiple targets can be identified simultaneously within a single sample. The system is also cost-effective and adaptable, lending itself to rapid detection scenarios where timely results are critical. Experimental validation within the patent demonstrates the nanoswitches' capability to identify specific DNA sequences and mismatch variants, underscoring their potential utility across multiple domains. 

                          https://suny.technologypublisher.com/files/sites/adobestock_237602801.jpeg
                          Photo for reference only, not a depiction of the invention.

                          Advantages:  
                          •    High specificity and sensitivity for detecting target molecules, minimizing false positives and negatives.
                          •    Rapid detection, enabling timely diagnostic and monitoring decisions.
                          •    Cost-effective composition, leveraging simple DNA oligonucleotides without requiring complex hardware.
                          •    Capability for multiplexed detection, allowing simultaneous analysis of multiple analytes.
                          •    Versatility in detection methods, compatible with common laboratory techniques such as fluorescence and gel electrophoresis.
                          •    Robust experimental validation confirms reliability and practical applicability. 

                          Applications:  
                          •    Medical diagnostics, including genetic testing and disease marker identification.
                          •    Environmental monitoring for detecting pollutants, pathogens, or other chemical analytes.
                          •    Biochemical research tools for analyzing DNA sequences, mutations, and molecular interactions.
                          •    Point-of-care testing where rapid and accurate detection is essential.
                          •    Multiplexed assay development, useful in situations requiring simultaneous detection of multiple targets. 

                          Intellectual Property Summary:
                          Issued patent 12,077,807

                          Stage of Development:
                          TRL 5

                          Licensing Status:
                          This technology is available for licensing.
                           

                          ]]>Tue, 05 May 2026 17:57:23 GMTIEA@rfsuny.orghttps://www.canberra-ip.com/tech?title=Fast%2c_Background-free_Detection_of_Nucleic_Acid_Sequences_Using_DNA_Nanoswitches15-14-010Wed, 06 May 2026 12:53:38 GMTBackground:Accurate detection of specific molecules, such as DNA sequences or other analytes, is fundamental in medical diagnostics, environmental monitoring, and biochemical research. Traditional detection methods often face challenges such as limited sensitivity, high cost, or slow processing times. To address these issues, researchers developed DNA nanostructures capable of responding to target molecules with measurable changes, aiming to create a detection system that is both highly specific and efficient.Technology Overview:https://suny.technologypublisher.com/files/sites/adobestock_237602801.jpegPhoto for reference only, not a depiction of the invention.Advantages: •    Rapid detection, enabling timely diagnostic and monitoring decisions.
                          •    Cost-effective composition, leveraging simple DNA oligonucleotides without requiring complex hardware.
                          •    Capability for multiplexed detection, allowing simultaneous analysis of multiple analytes.
                          •    Versatility in detection methods, compatible with common laboratory techniques such as fluorescence and gel electrophoresis.
                          •    Robust experimental validation confirms reliability and practical applicability.]]>Applications: •    Environmental monitoring for detecting pollutants, pathogens, or other chemical analytes.
                          •    Biochemical research tools for analyzing DNA sequences, mutations, and molecular interactions.
                          •    Point-of-care testing where rapid and accurate detection is essential.
                          •    Multiplexed assay development, useful in situations requiring simultaneous detection of multiple targets.]]>Intellectual Property Summary:Issued patent 12,077,807Stage of Development:TRL 5Licensing Status:This technology is available for licensing.KennethHalvorsenSenior Research Scientist, Advanced Instrumentation FacilityThe RNA Institutekhalvorsen@albany.edu(518) 591-8816WesleyWongAssistant Professorwong@idi.harvard.edu(617) 713-8383Arun RichardChandrasekaranResearch Scientist, Halvorsen LabThe RNA Institutearun@albany.edu(518) 591-8849PatrickNelsonLife Sciences IP Managerpatrick.nelson@rfsuny.org University at Albany| Technology Classifications > Biomedical Science and Engineering]]>Falsehttps://www.canberra-ip.com/tech?title=Agility_Trainer_2.0%3a_Dynamic_Treadmill_Force_Field_System_for_Balance_Rehabilitation 
                          ]]>Tue, 05 May 2026 17:42:28 GMTdragos@northwestern.eduhttps://www.canberra-ip.com/tech?title=Agility_Trainer_2.0%3a_Dynamic_Treadmill_Force_Field_System_for_Balance_Rehabilitation2017-103Tue, 05 May 2026 18:23:55 GMTDevices, Health IT, Medical device, Prosthesis/Rehabilitation, MichaelMoellerInvention ManagerInnovation and New Venturesmichael.moeller@northwestern.edu847-491-4201 Healthcare Devices, Tools & IT]]>Falsehttps://www.canberra-ip.com/tech/Minimally_Invasive_Wireless_Neurotechnology_PlatformInvention Description
                          Treating and monitoring deep brain regions is challenging due to the limitations of current neurotechnology, which often relies on invasive implants or inefficient transcranial methods. These approaches can involve surgical risks, bulky hardware, and limited precision in targeting specific neural pathways. Additionally, delivering energy or therapeutic effects deep within the brain remains difficult without compromising safety or effectiveness.
                           
                          Researchers at Arizona State University have developed an advanced neurotechnology that utilizes a novel and unexplored anatomical pathway to deliver electromagnetic energy directly to deep brain regions. This system enables wireless, battery-free neurostimulation and sensing with improved power efficiency and communication reliability. It allows precise modulation of neural pathways involved in conditions such as opioid addiction and chronic pain, and supports targeted hyperthermia treatment for deep brain tumors like pituitary adenomas. By avoiding invasive implants and overcoming the limitations of traditional transcranial approaches, the platform improves safety, reduces device size, and enhances scalability for clinical use.
                           
                          This novel, minimally invasive platform enables efficient wireless delivery of RF electromagnetic energy to deep brain structures for neuromodulation, sensing, and therapy.
                           
                          Potential Applications
                          • Wireless closed-loop neurostimulation systems for epilepsy and neurological disorders
                          • Noninvasive neuromodulation therapies targeting addiction and chronic pain pathways
                          • Precise hyperthermia treatment for deep brain tumors including pituitary adenomas
                          • Implantable, battery-free neuromodulation and neural sensing devices
                          • Research tools for investigating neural activity modulation and brain disorder treatment
                          • Medical devices addressing opioid addiction and postoperative pain based on electrophysiological modulation
                          Benefits and Advantages
                          • Minimally invasive access via wireless devices
                          • Wireless and battery-free operation for long-term implantable neurostimulation and sensing
                          • Enhanced electromagnetic power delivery efficiency and communication through a favorable anatomical path reducing signal attenuation
                          • Wide frequency range utilization enabling versatile RF pulse designs
                          • Reduced hardware footprint
                          • Improved safety profile with diminished tissue heating and off-target effects
                          • Capability for precise localized stimulation and thermal control
                          • Supports multifunctional applications including electrical stimulation, sensing, and hyperthermia therapy
                          • Compatible with magnetic nanomaterial-enhanced tumor treatments
                          ]]>Mon, 04 May 2026 20:43:17 GMTip@skysonginnovations.comhttps://www.canberra-ip.com/tech/Minimally_Invasive_Wireless_Neurotechnology_PlatformM25-323LMon, 04 May 2026 20:43:17 GMTSung-MinSohnAssistant ProfessorSBHSEsmsohn@asu.eduJovanHeusserDirector of Licensing and Business Developmentjovan.heusser@skysonginnovations.comLife Science (All LS Techs)| Medical Devices| Neurodegenerative Disease TechnologiesFalsehttps://www.canberra-ip.com/tech?title=ATR%24FTIR_spectroscopy_of_saliva_and_machine_learning_as_a_screening_test_for_the_Sj%c3%b6gren_diseaseThis technology uses saliva analysis with infrared spectroscopy and machine learning to provide a fast, non-invasive, and accurate test for Sjögren’s Disease, filtering out unreliable data to improve diagnosis and potentially screen for other diseases. 

                          Background:
                          Sjögren’s disease is a chronic autoimmune disorder that primarily targets the body’s moisture-producing glands, leading to symptoms such as dry mouth and dry eyes. Diagnosing this condition is particularly challenging due to the overlap of its symptoms with other diseases and the absence of a single, definitive biomarker. The field of non-invasive diagnostics has therefore become increasingly important, as clinicians and researchers seek reliable, accessible, and patient-friendly methods for early detection and monitoring of autoimmune diseases. Saliva, as a readily available and non-invasively collectible biofluid, offers a promising window into the body’s biochemical state, making it an attractive medium for disease screening and diagnosis. Current diagnostic approaches for Sjögren’s disease, such as minor salivary gland biopsies, Schirmer’s tests, and serological assays, are often invasive, time-consuming, and lack sufficient specificity and sensitivity. These methods can be uncomfortable for patients, require specialized clinical settings, and may not always yield conclusive results, especially in early or atypical cases. Additionally, traditional spectroscopic and chemometric techniques used to analyze saliva or other biofluids struggle to distinguish diagnostically relevant signals from noise or unrelated biochemical variations, particularly given the heterogeneity of biological samples. This limitation hampers the effectiveness of machine learning models, as irrelevant or low-quality data can lead to poor generalization, reduced interpretability, and increased risk of misclassification—highlighting the pressing need for more robust, accurate, and user-friendly diagnostic solutions.

                          Technology Overview:  
                          This technology offers a non-invasive diagnostic solution for Sjögren’s Disease by integrating attenuated total reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy of saliva with a sophisticated machine learning framework. Saliva samples are analyzed using ATR-FTIR to generate comprehensive spectral fingerprints that reflect the biochemical composition associated with disease states. These high-dimensional spectra are then processed by an artificial neural network, which is enhanced by Monte Carlo Dropout (MCD) uncertainty estimation. The MCD mechanism serves as a critical preprocessing step, filtering out spectra with low classification confidence to ensure that only diagnostically relevant and high-quality data are used for model training. This approach not only increases the accuracy of disease detection but also supports rapid, repeatable, and painless sample collection, making it suitable for point-of-care diagnostics, home testing, and longitudinal monitoring. What differentiates this technology is its innovative use of MCD-based uncertainty estimation to address a fundamental challenge in biospectroscopic diagnostics: the inherent variability and noise within biofluid samples, where only a subset of spectra may be diagnostically informative. By systematically identifying and excluding ambiguous or uninformative spectra before model training, the solution enhances the interpretability, generalization, and robustness of the neural network classifier. This results in improved diagnostic performance, reduced risk of overfitting, and greater resilience to sample heterogeneity—critical for diseases like Sjögren’s, where biomarkers are sparse and unevenly distributed. The methodology is broadly applicable to other diseases and biofluids, enabling scalable, affordable, and accessible diagnostics across diverse clinical and research settings, and represents a significant advancement in the intersection of vibrational spectroscopy and artificial intelligence. 

                          https://suny.technologypublisher.com/files/sites/adobestock_330216893.jpeg
                          Photo for reference only, not a depiction of the invention.

                          Advantages:  
                          •    Non-invasive and painless saliva-based diagnostic method for Sjögren’s Disease
                          •    Rapid and accessible screening suitable for point-of-care and home testing
                          •    Improved diagnostic accuracy through machine learning classification of biochemical spectral fingerprints
                          •    Enhanced model robustness and interpretability via Monte Carlo Dropout uncertainty filtering of low-confidence spectra
                          •    Reduction of noise and irrelevant data, leading to better generalization and reliability
                          •    Applicable to longitudinal monitoring and disease progression tracking
                          •    Potentially extendable to other diseases and biofluids with heterogeneous diagnostic signals
                          •    Supports development of scalable, affordable diagnostic tools for diverse clinical and research settings 

                          Applications:  
                          •    Point-of-care Sjögren’s disease screening
                          •    Home-based saliva diagnostic kits
                          •    Longitudinal disease monitoring tools
                          •    Portable autoimmune disease diagnostics
                          •    Research tool for biofluid analysis 

                          Intellectual Property Summary:
                          Patent application filed

                          Stage of Development:
                          Inquire for more information

                          Licensing Status:
                          This technology is available for licensing.
                           

                          ]]>Mon, 04 May 2026 18:23:44 GMTIEA@rfsuny.orghttps://www.canberra-ip.com/tech?title=ATR%24FTIR_spectroscopy_of_saliva_and_machine_learning_as_a_screening_test_for_the_Sj%c3%b6gren_disease010-26-03Tue, 05 May 2026 17:26:19 GMTBackground:Technology Overview:https://suny.technologypublisher.com/files/sites/adobestock_330216893.jpegPhoto for reference only, not a depiction of the invention.Advantages: •    Rapid and accessible screening suitable for point-of-care and home testing
                          •    Improved diagnostic accuracy through machine learning classification of biochemical spectral fingerprints
                          •    Enhanced model robustness and interpretability via Monte Carlo Dropout uncertainty filtering of low-confidence spectra
                          •    Reduction of noise and irrelevant data, leading to better generalization and reliability
                          •    Applicable to longitudinal monitoring and disease progression tracking
                          •    Potentially extendable to other diseases and biofluids with heterogeneous diagnostic signals
                          •    Supports development of scalable, affordable diagnostic tools for diverse clinical and research settings]]>Applications: •    Home-based saliva diagnostic kits
                          •    Longitudinal disease monitoring tools
                          •    Portable autoimmune disease diagnostics
                          •    Research tool for biofluid analysis]]>Intellectual Property Summary:Patent application filedStage of Development:Inquire for more informationLicensing Status:This technology is available for licensing.IgorLednevDistinguished ProfessorChemistryilednev@albany.edu(518) 591-8863BhavikkumarVyasPhD studentChemistrybvyas@albany.edu5185918865JürgenPoppAdjunct ProfessorChemistryjuergen.popp@leibniz-ipht.de+49 3641 206300OlegRyabchykovResearch AssociatePhotonic Data Science Departmentoleg.ryabchykov@leibniz-ipht.de+49 (0)3641 206 350diagnostics, Salivary biomarkers, Sjogren Disease, spectroscopy, Technologies, PatrickNelsonLife Sciences IP Managerpatrick.nelson@rfsuny.org University at Albany| Technology Classifications > Diagnostics]]>Falsehttps://www.canberra-ip.com/tech/Temporal_Control_of_CRISPR-Cas9_using_Bio-orthogonal_Chemistry.This technology enables precise, time-controlled activation or deactivation of CRISPR-Cas9 genome editing using biocompatible chemical reactions, reducing off-target effects and improving the safety and accuracy of gene editing for research and therapeutic applications. 

                          Background:
                          Genome editing technologies, particularly CRISPR-Cas9, have revolutionized the field of molecular biology and therapeutic development by enabling precise, targeted modifications to the genetic material of living organisms. These tools hold immense promise for treating genetic diseases, advancing functional genomics research, and developing novel biotechnological applications. However, the power of genome editing is accompanied by significant challenges, especially in clinical and therapeutic contexts where safety and specificity are paramount. A critical aspect of ensuring safe genome editing is the ability to tightly regulate when and where the editing machinery is active, minimizing unintended consequences and maximizing therapeutic benefit. Despite the transformative potential of CRISPR-Cas9, current approaches to controlling its activity often fall short in providing precise temporal regulation. Conventional strategies, such as inducible promoters, protein engineering, or optogenetic systems, can be limited by slow response times, lack of biocompatibility, or complexity in implementation. These limitations contribute to a persistent problem: off-target genome editing, where the CRISPR-Cas9 system inadvertently modifies DNA sequences similar, but not identical, to the intended target. Such off-target effects can result in unwanted genetic changes, posing significant safety risks and hindering the clinical translation of gene-editing therapies. The inability to rapidly and reversibly control CRISPR-Cas9 activity in a biocompatible manner remains a major barrier to the broader adoption and safe application of genome editing technologies.

                          Technology Overview:  
                          This technology enables precise temporal control of the CRISPR-Cas9 genome editing system by integrating bio-orthogonal chemistry, specifically the rapid and biocompatible reaction between trans-cyclooctene (TCO) and tetrazine (Tz). The system utilizes small molecule RNA tags and corresponding small molecule activators or suppressors to regulate the nuclease activity of CRISPR-Cas9. By introducing these chemical components, researchers can activate or deactivate the gene-editing machinery at specific times, thereby tightly controlling when genome editing occurs. This approach is particularly valuable for minimizing off-target effects, as it restricts the window during which CRISPR-Cas9 is active, reducing the likelihood of unintended DNA modifications. What differentiates this technology is its reliance on the TCO-Tz bio-orthogonal reaction, which is exceptionally fast and highly compatible with biological systems, allowing for seamless integration into living cells and organisms without disrupting native biochemical processes. Unlike alternative methods that may require complex protein engineering, light-based activation, or less biocompatible chemical systems, this solution offers a straightforward, efficient, and robust means of temporal control. Its design ensures that the CRISPR-Cas9 system can be precisely modulated in vivo, making it especially attractive for therapeutic applications where safety and specificity are paramount. This level of control addresses a significant challenge in the field and positions the technology as a valuable tool for both research and clinical gene editing.

                          https://suny.technologypublisher.com/files/sites/adobestock_1632870774.jpeg
                          Photo for reference only, not a depiction of the invention.

                          Advantages:  
                          •    Enables precise temporal control of CRISPR-Cas9 activity for targeted genome editing
                          •    Minimizes off-target DNA modifications, enhancing safety and specificity
                          •    Utilizes a fast, highly biocompatible bio-orthogonal reaction (TCO-Tz) suitable for in vivo applications
                          •    Employs small molecule RNA tags and activators/suppressors for flexible regulation
                          •    Reduces the risk of unintended genetic alterations, facilitating clinical translation of gene therapies
                          •    Offers a simpler alternative to complex protein engineering or light-activated systems
                          •    Applicable broadly in gene therapy, research, and development of CRISPR-based therapeutics 

                          Applications:  
                          •    Precision gene therapy development
                          •    Controlled in vivo genome editing
                          •    Temporal functional genomics studies
                          •    Safe CRISPR-based drug discovery 

                          Intellectual Property Summary:
                          Patent application filed 19/316,343

                          Stage of Development:
                          TRL 4

                          Licensing Status:
                          This technology is available for licensing.

                          ]]>Mon, 04 May 2026 18:19:57 GMTIEA@rfsuny.orghttps://www.canberra-ip.com/tech/Temporal_Control_of_CRISPR-Cas9_using_Bio-orthogonal_Chemistry.010-24-37Tue, 05 May 2026 17:25:59 GMTThis technology enables precise, time-controlled activation or deactivation of CRISPR-Cas9 genome editing using biocompatible chemical reactions, reducing off-target effects and improving the safety and accuracy of gene editing for research and therapeutic applications.Background:Genome editing technologies, particularly CRISPR-Cas9, have revolutionized the field of molecular biology and therapeutic development by enabling precise, targeted modifications to the genetic material of living organisms. These tools hold immense promise for treating genetic diseases, advancing functional genomics research, and developing novel biotechnological applications. However, the power of genome editing is accompanied by significant challenges, especially in clinical and therapeutic contexts where safety and specificity are paramount. A critical aspect of ensuring safe genome editing is the ability to tightly regulate when and where the editing machinery is active, minimizing unintended consequences and maximizing therapeutic benefit. Despite the transformative potential of CRISPR-Cas9, current approaches to controlling its activity often fall short in providing precise temporal regulation. Conventional strategies, such as inducible promoters, protein engineering, or optogenetic systems, can be limited by slow response times, lack of biocompatibility, or complexity in implementation. These limitations contribute to a persistent problem: off-target genome editing, where the CRISPR-Cas9 system inadvertently modifies DNA sequences similar, but not identical, to the intended target. Such off-target effects can result in unwanted genetic changes, posing significant safety risks and hindering the clinical translation of gene-editing therapies. The inability to rapidly and reversibly control CRISPR-Cas9 activity in a biocompatible manner remains a major barrier to the broader adoption and safe application of genome editing technologies.Technology Overview:This technology enables precise temporal control of the CRISPR-Cas9 genome editing system by integrating bio-orthogonal chemistry, specifically the rapid and biocompatible reaction between trans-cyclooctene (TCO) and tetrazine (Tz). The system utilizes small molecule RNA tags and corresponding small molecule activators or suppressors to regulate the nuclease activity of CRISPR-Cas9. By introducing these chemical components, researchers can activate or deactivate the gene-editing machinery at specific times, thereby tightly controlling when genome editing occurs. This approach is particularly valuable for minimizing off-target effects, as it restricts the window during which CRISPR-Cas9 is active, reducing the likelihood of unintended DNA modifications. What differentiates this technology is its reliance on the TCO-Tz bio-orthogonal reaction, which is exceptionally fast and highly compatible with biological systems, allowing for seamless integration into living cells and organisms without disrupting native biochemical processes. Unlike alternative methods that may require complex protein engineering, light-based activation, or less biocompatible chemical systems, this solution offers a straightforward, efficient, and robust means of temporal control. Its design ensures that the CRISPR-Cas9 system can be precisely modulated in vivo, making it especially attractive for therapeutic applications where safety and specificity are paramount. This level of control addresses a significant challenge in the field and positions the technology as a valuable tool for both research and clinical gene editing.https://suny.technologypublisher.com/files/sites/adobestock_1632870774.jpegPhoto for reference only, not a depiction of the invention.Advantages: •    Minimizes off-target DNA modifications, enhancing safety and specificity
                          •    Utilizes a fast, highly biocompatible bio-orthogonal reaction (TCO-Tz) suitable for in vivo applications
                          •    Employs small molecule RNA tags and activators/suppressors for flexible regulation
                          •    Reduces the risk of unintended genetic alterations, facilitating clinical translation of gene therapies
                          •    Offers a simpler alternative to complex protein engineering or light-activated systems
                          •    Applicable broadly in gene therapy, research, and development of CRISPR-based therapeutics]]>Applications: •    Controlled in vivo genome editing
                          •    Temporal functional genomics studies
                          •    Safe CRISPR-based drug discovery]]>Intellectual Property Summary:Patent application filed 19/316,343Stage of Development:TRL 4Licensing Status:This technology is available for licensing.MaksimRoyzenAssociate ProfessorChemistrymroyzen@albany.edu(518) 437-4463BhoomikaPanditGraduate StudentChemistrybpandit@albany.edubiochemistry, CRISPR, Technologies, PatrickNelsonLife Sciences IP Managerpatrick.nelson@rfsuny.org University at Albany| Technology Classifications > Gene Therapy]]>Falsehttps://www.canberra-ip.com/tech?title=Bruton%27s_Tyrosine_Kinase_as_Anti-Cancer_Drug_TargetThis technology identifies Bruton's Tyrosine Kinase (BTK) as a novel target in breast cancer therapy and provides methods for treatment and diagnosis by inhibiting a specific BTK variant. 

                          Background:
                          Protein tyrosine kinases (PTKs) are essential enzymes involved in cellular communication and regulation, often playing a significant role in cancer development. Bruton's Tyrosine Kinase (BTK), traditionally known for its role in B cell development, has been found to be critical for the survival of certain breast cancer cells. Research revealed that breast tumor cells express a variant form of BTK at elevated levels compared to normal cells, establishing a new perspective on BTK’s function beyond the immune system and suggesting it as a potential therapeutic target in oncology.

                          Technology Overview:  
                          This technology centers on the discovery and exploitation of a specific variant of BTK with an amino-terminal extension that is predominantly expressed in breast cancer cells. Using RNA interference (RNAi) screening techniques, researchers identified that suppressing BTK expression leads to reduced survival of breast cancer cells. The technology includes methods for targeting this BTK variant with inhibitors, especially RNAi-based therapeutics, to selectively impair cancer cell growth. Furthermore, it proposes diagnostic strategies to detect the BTK variant as a biomarker for breast cancer, enabling more precise diagnosis and monitoring. The innovation lies in recognizing BTK’s critical role in tumor development outside its known immune function and providing tailored approaches for both treatment and detection by focusing on the variant uniquely upregulated in cancerous tissue. This dual therapeutic and diagnostic potential offers a promising avenue for improving breast cancer management. 

                          https://suny.technologypublisher.com/files/sites/adobestock_837848980.jpeg
                          Photo for reference only, not a depiction of the invention.

                          Advantages:  
                          •    Target specificity: Focuses on a BTK variant uniquely elevated in breast cancer cells, allowing precise therapeutic targeting.
                          •    Dual functionality: Enables both treatment through BTK inhibition and diagnosis via detection of the BTK variant.
                          •    Innovative approach: Utilizes RNA interference technology for selective suppression of cancer cell proliferation.
                          •    Potential for improved outcomes: By directly targeting essential cancer cell survival pathways, it may lead to more effective therapies with fewer side effects.
                          •    Foundation for drug development: Offers a basis for creating novel BTK inhibitors tailored to breast cancer applications. 

                          Applications:  
                          •    Development of anti-cancer drugs aimed at inhibiting BTK activity in breast tumors.
                          •    Diagnostic tools for detecting the presence or levels of the BTK variant as a biomarker for breast cancer.
                          •    Personalized medicine approaches that use BTK variant status to guide treatment decisions.
                          •    Research applications in understanding cancer cell survival mechanisms related to tyrosine kinase signaling.
                          •    Potential expansion to other cancers where BTK variants may play a role in disease progression. 

                          Intellectual Property Summary:
                          Issued patent 8,513,212

                          Stage of Development:
                          TRL 4

                          Licensing Status:
                          This technology is available for licensing.

                          ]]>Mon, 04 May 2026 18:16:25 GMTIEA@rfsuny.orghttps://www.canberra-ip.com/tech?title=Bruton%27s_Tyrosine_Kinase_as_Anti-Cancer_Drug_Target08-19-010Tue, 05 May 2026 17:25:32 GMTBackground:Technology Overview:https://suny.technologypublisher.com/files/sites/adobestock_837848980.jpegPhoto for reference only, not a depiction of the invention.Advantages: •    Dual functionality: Enables both treatment through BTK inhibition and diagnosis via detection of the BTK variant.
                          •    Innovative approach: Utilizes RNA interference technology for selective suppression of cancer cell proliferation.
                          •    Potential for improved outcomes: By directly targeting essential cancer cell survival pathways, it may lead to more effective therapies with fewer side effects.
                          •    Foundation for drug development: Offers a basis for creating novel BTK inhibitors tailored to breast cancer applications.]]>Applications: •    Diagnostic tools for detecting the presence or levels of the BTK variant as a biomarker for breast cancer.
                          •    Personalized medicine approaches that use BTK variant status to guide treatment decisions.
                          •    Research applications in understanding cancer cell survival mechanisms related to tyrosine kinase signaling.
                          •    Potential expansion to other cancers where BTK variants may play a role in disease progression.]]>Intellectual Property Summary:Issued patent 8,513,212Stage of Development:TRL 4Licensing Status:This technology is available for licensing.DouglasConklinAssociate ProfessorBiomedical Sciencedconklin@albany.edu(518) 591-7154AntonisKourtidisAssistant ProfessorRegenerative Medicine and Cell Biologykourtidi@musc.edu(843) 792-9170CherylEifertPersonlized Medicine Scientistchereifert@gmail.combreast cancer, cancer, TAF, Technologies, therapeutic targets, PatrickNelsonLife Sciences IP Managerpatrick.nelson@rfsuny.org Therapeutics and Vaccines| Technology Classifications > Biomedical Science and Engineering| Campus > University at Albany]]>Falsehttps://www.canberra-ip.com/tech?title=Spectroscopic_Method_for_Diagnostics_of_Alzheimer%27s_DiseaseThis technology provides a non-invasive, spectroscopic method using Raman spectroscopy to diagnose and monitor Alzheimer’s disease by analyzing biochemical changes in blood serum. 

                          Background:
                          Alzheimer’s disease presents significant diagnostic challenges, often requiring invasive or costly procedures with limited early detection capabilities. Traditional diagnostic methods lack efficiency for timely and accurate identification, which is crucial for managing disease progression. Research into spectroscopic techniques revealed the potential for detecting molecular changes associated with Alzheimer’s in blood serum, leading to the development of this innovative diagnostic approach.

                          Technology Overview:  
                          This technology employs Raman spectroscopy, specifically including Surface Enhanced Raman Spectroscopy (SERS), to obtain a unique spectroscopic signature from a subject’s blood serum sample. By analyzing this signature, the method detects biochemical markers indicative of Alzheimer’s disease. The Raman spectroscopic signature reflects molecular vibrations that change as the disease progresses, allowing differentiation between healthy individuals, Alzheimer’s patients, and those with other types of dementia. Advanced statistical tools such as support vector machines (SVM) and artificial neural networks (ANN) are integrated to analyze the spectroscopic data. These machine learning methods classify the spectral signatures with high accuracy, enhancing diagnostic reliability. Experimentation has validated this approach’s effectiveness in identifying Alzheimer’s disease and monitoring its progression. The value proposition lies in its non-invasive nature, employing blood serum samples rather than more invasive brain imaging or cerebrospinal fluid analysis. It offers a cost-effective, rapid, and scalable tool for early diagnosis and disease monitoring, potentially transforming patient care by enabling timely therapeutic interventions. 

                          https://suny.technologypublisher.com/files/sites/adobestock_733997563.jpeg
                          Photo for reference only, not a depiction of the invention.

                          Advantages:  
                          •    Non-invasive testing method using easily accessible blood serum samples.
                          •    High diagnostic accuracy facilitated by advanced machine learning classification.
                          •    Capability to distinguish Alzheimer’s disease from other forms of dementia.
                          •    Cost-effective and rapid compared to traditional imaging or biochemical tests.
                          •    Supports early detection and continuous monitoring of disease progression.
                          •    Utilizes Surface Enhanced Raman Spectroscopy to improve sensitivity and specificity. 

                          Applications:  
                          •    Clinical diagnosis of Alzheimer’s disease in healthcare settings.
                          •    Screening tool for early detection in at-risk populations.
                          •    Monitoring disease progression in diagnosed patients for personalized treatment planning.
                          •    Research tool for studying biochemical changes related to neurodegenerative diseases.
                          •    Supportive technology in developing new Alzheimer’s therapies by tracking biochemical responses. 

                          Intellectual Property Summary:
                          Issued patent 9,891,108

                          Stage of Development:
                          TRL 4

                          Licensing Status:
                          This technology is available for licensing.
                           

                          ]]>Mon, 04 May 2026 18:14:02 GMTIEA@rfsuny.orghttps://www.canberra-ip.com/tech?title=Spectroscopic_Method_for_Diagnostics_of_Alzheimer%27s_Disease10-16-010Wed, 06 May 2026 12:54:40 GMTBackground:Technology Overview:https://suny.technologypublisher.com/files/sites/adobestock_733997563.jpegPhoto for reference only, not a depiction of the invention.Advantages: •    High diagnostic accuracy facilitated by advanced machine learning classification.
                          •    Capability to distinguish Alzheimer’s disease from other forms of dementia.
                          •    Cost-effective and rapid compared to traditional imaging or biochemical tests.
                          •    Supports early detection and continuous monitoring of disease progression.
                          •    Utilizes Surface Enhanced Raman Spectroscopy to improve sensitivity and specificity.]]>Applications: •    Screening tool for early detection in at-risk populations.
                          •    Monitoring disease progression in diagnosed patients for personalized treatment planning.
                          •    Research tool for studying biochemical changes related to neurodegenerative diseases.
                          •    Supportive technology in developing new Alzheimer’s therapies by tracking biochemical responses.]]>Intellectual Property Summary:Issued patent 9,891,108Stage of Development:TRL 4Licensing Status:This technology is available for licensing.IgorLednevDistinguished ProfessorChemistryilednev@albany.edu(518) 591-8863Alzheimer's, blood, diagnostics, neurodegeneration, Raman spectroscopy, statistical analysis, TAF, Technologies, vibrational spectroscopy, PatrickNelsonLife Sciences IP Managerpatrick.nelson@rfsuny.org Diagnostics| Campus > University at Albany]]>Falsehttps://www.canberra-ip.com/tech?title=Diagnosing_Alzheimer%27s_via_Raman_Spectroscopic_Analysis_of_SalivaThis technology provides a non-invasive method for early detection of cognitive diseases using spectroscopic analysis of saliva samples combined with advanced statistical and neural network models. 

                          Background:
                          Cognitive diseases such as Alzheimer's and mild cognitive impairment (MCI) represent significant challenges in healthcare due to their subtle early symptoms and the difficulty of timely diagnosis. Traditional diagnostic methods often rely on invasive procedures, costly imaging, or subjective clinical assessments, which can delay effective treatment and intervention. Recognizing the need for a more accessible and accurate diagnostic approach, researchers developed a system that leverages saliva—a readily obtainable biofluid—and advanced spectroscopic analysis to identify disease-specific biomarkers.

                          Technology Overview:  
                          This innovative technology employs spectroscopic techniques, including Raman and Fourier Transform Infrared (FTIR) spectroscopy, to analyze saliva samples and generate unique spectroscopic signatures corresponding to various cognitive conditions. By capturing the molecular composition reflected in these signatures, the system translates biological changes associated with cognitive diseases into measurable data. A key feature of this approach is the integration of a sophisticated computing system that uses neural networks and predetermined statistical models to interpret the spectroscopic data. These models have been trained to correlate specific spectral patterns with cognitive states such as healthy, Alzheimer's disease, or mild cognitive impairment. This process enables objective classification based on biochemical markers rather than solely clinical observation. The system design includes a spectroscopy device optimized for saliva analysis, enhancing ease of sample collection and testing. Additionally, the use of machine learning algorithms allows continuous improvement and calibration of the detection accuracy as more data becomes available. Overall, this technology offers a rapid, non-invasive, and scalable solution for early cognitive disease detection, potentially transforming patient care by facilitating timely diagnosis and personalized treatment planning. 

                          https://suny.technologypublisher.com/files/sites/adobestock_194754842.jpeg
                          Photo for reference only, not a depiction of the invention.

                          Advantages:  
                          •    Non-invasive testing using saliva samples, improving patient comfort and compliance.
                          •    Rapid and accurate detection through advanced spectroscopic analysis combined with neural networks.
                          •    Ability to distinguish between healthy, Alzheimer's, and mild cognitive impairment conditions effectively.
                          •    Reduced reliance on costly and invasive diagnostic procedures like imaging or biopsies.
                          •    Scalable and adaptable system capable of continuous learning and improvement with additional data.
                          •    Potential to facilitate earlier diagnosis, enabling timely intervention and better patient outcomes. 

                          Applications:  
                          •    Clinical screening and early diagnosis of cognitive impairments such as Alzheimer's disease and MCI.
                          •    Monitoring disease progression and response to treatment in patients with cognitive disorders.
                          •    Use in healthcare settings as a cost-effective alternative to traditional diagnostic methods.
                          •    Integration into routine health check-ups for populations at risk of cognitive decline.
                          •    Research tool for understanding biochemical markers associated with cognitive diseases. 

                          Intellectual Property Summary:
                          Patent application filed 17/368,251

                          Stage of Development:
                          TRL 4

                          Licensing Status:
                          This technology is available for licensing.
                           

                          ]]>Mon, 04 May 2026 18:10:45 GMTIEA@rfsuny.orghttps://www.canberra-ip.com/tech?title=Diagnosing_Alzheimer%27s_via_Raman_Spectroscopic_Analysis_of_Saliva010-18-13Tue, 05 May 2026 17:24:37 GMTThis technology provides a non-invasive method for early detection of cognitive diseases using spectroscopic analysis of saliva samples combined with advanced statistical and neural network models.Background:Technology Overview:https://suny.technologypublisher.com/files/sites/adobestock_194754842.jpegPhoto for reference only, not a depiction of the invention.Advantages: •    Rapid and accurate detection through advanced spectroscopic analysis combined with neural networks.
                          •    Ability to distinguish between healthy, Alzheimer's, and mild cognitive impairment conditions effectively.
                          •    Reduced reliance on costly and invasive diagnostic procedures like imaging or biopsies.
                          •    Scalable and adaptable system capable of continuous learning and improvement with additional data.
                          •    Potential to facilitate earlier diagnosis, enabling timely intervention and better patient outcomes.]]>Applications: •    Monitoring disease progression and response to treatment in patients with cognitive disorders.
                          •    Use in healthcare settings as a cost-effective alternative to traditional diagnostic methods.
                          •    Integration into routine health check-ups for populations at risk of cognitive decline.
                          •    Research tool for understanding biochemical markers associated with cognitive diseases.]]>Intellectual Property Summary:Patent application filed 17/368,251Stage of Development:TRL 4Licensing Status:This technology is available for licensing.IgorLednevDistinguished ProfessorChemistryilednev@albany.edu(518) 591-8863NicoleRalbovskyChemistrynralbovsky@albany.edu(518) 442-4442CayAnderson-HanleyAssociate Professorandersoc@union.edu(518) 388-6355Alzheimer's, diagnostics, saliva, solar cells, TAF, Technologies, PatrickNelsonLife Sciences IP Managerpatrick.nelson@rfsuny.org Diagnostics| Campus > University at Albany]]>Falsehttps://www.canberra-ip.com/tech/Advanced_Water-Soluble_Polyurethane_DispersionsInvention Description
                          Polyurethanes (PUs) are highly versatile materials that offer researchers and industry professionals great molecular customizability, allowing for applications ranging from biomedical devices to specialized coatings and adhesives. Conventional solvent-based polyurethanes pose significant environmental and health risks due to high emissions of volatile organic compounds (VOCs) and free isocyanates. Driven by stricter environmental regulations and expanding industrial applications, such as water purification and apparel, interest in water-soluble PUs (WPUs) has grown significantly.
                           
                          Prof. Yoan Simon at Arizona State University has developed novel water-soluble polyurethane dispersions as well as synthesis routes. These WPUs overcome the environmental and health concerns of traditional solvent-based systems and their unique structure provides exceptional stability, particularly in high-salt environments where conventional water-based polyurethanes commonly fail. The polymer’s structure can be fine-tuned to control self-assembly, rheological behavior, and final film properties, resulting in highly versatile and functional materials.
                           
                          These WPUs deliver an eco-friendly alternative to solvent-based polyurethanes with reduced VOC emissions, combining advantages such as biodegradability, biocompatibility, and antifouling properties that are highly desirable for biomedical devices, cosmetics, coatings, and other formulations.
                           
                          Potential Applications
                          • Coatings and Paints: High-performance, eco-friendly formulations for various surfaces
                          • Cosmetics: Stable and gentle ingredients for personal care products
                          • Energy: Enhanced oil recovery applications where high-salinity tolerance is crucial
                          • Biomedical: Potential use in bioprinting tissue scaffolds and other biological applications requiring biocompatible materials
                          Benefits and Advantages
                          • The water-based formulation reduces the environmental impact and health risks associated with traditional solvent-based polyurethane manufacturing and use
                          • Enhanced Stability: Exhibits robust stability across a wide range of salt concentrations, a significant improvement over traditional water-based polyurethanes
                          • Highly Customizable: The mechanical, thermal, and rheological properties can be precisely tuned by adjusting the zwitterionic content and polymer structure
                          • Versatile Functionality: Suitable for a broad spectrum of applications due to its adaptable nature and stable performance
                          • Provides a high-performance alternative for applications requiring both environmental compliance and material robustness
                          ]]>Mon, 04 May 2026 17:55:25 GMTip@skysonginnovations.comhttps://www.canberra-ip.com/tech/Advanced_Water-Soluble_Polyurethane_DispersionsM26-016PMon, 04 May 2026 17:55:25 GMTYoanSimonAssociate ProfessorSchool of Molecular Sciencesyoan.simon@asu.eduAdvanced manufacturing, Biomedical devices, Cosmetics, Paints and Coatings, Petroleum and Fuel, Physical SciencesTeamAdvanced Materials/Nanotechnology| Manufacturing/Construction/Mechanical| Physical ScienceFalsehttps://www.canberra-ip.com/tech/Structurally_and_Functionally_Diverse_Heterocyclic_Dipeptide_Isosteres_and_Their_Derivatives_as_Antimicrobial_Agents_and_Peptidomimetic_Building_BlocksThis technology enables rapid, modular synthesis of diverse heterocyclic dipeptide isosteres with potent antimicrobial activity, which can be easily incorporated into peptides to create stable, bioactive molecules for drug discovery and therapeutic applications. 

                          Background:
                          The field of antimicrobial drug discovery and peptidomimetic development is of critical importance due to the escalating threat of multidrug-resistant (MDR) bacterial infections and the inherent limitations of traditional peptide therapeutics. Conventional peptides, while highly specific and potent, suffer from poor metabolic stability and rapid degradation in biological environments, limiting their clinical utility. There is a pressing need for new molecular scaffolds that not only exhibit potent antimicrobial activity but also possess enhanced pharmacokinetic properties, such as increased rigidity and resistance to enzymatic breakdown. Furthermore, expanding the chemical diversity of peptidomimetic building blocks is essential for developing next-generation therapeutics capable of targeting a broader range of biological processes, including protein–protein interactions and resistant bacterial strains. Current approaches to synthesizing dipeptide isosteres and heterocyclic peptidomimetics are hampered by several significant challenges. Traditional synthetic methods often yield low product quantities and lack the functional group tolerance necessary for constructing structurally diverse libraries. This restricts the exploration of new chemical space and limits the ability to optimize biological activity through structure–activity relationship (SAR) studies. Additionally, the integration of these scaffolds into peptide synthesis workflows is frequently inefficient, impeding the rapid generation and evaluation of novel compounds. As a result, the pace of discovery for new antimicrobial agents and stable peptidomimetics remains insufficient to address the urgent need for effective treatments against MDR pathogens and to expand the toolkit available for chemical biology and therapeutic development.

                          Technology Overview:  
                          This technology is a modular synthetic platform designed for the efficient generation of structurally and functionally diverse heterocyclic dipeptide isosteres and their derivatives. At its core, the platform employs an amination process to produce heterocyclic amino esters. These intermediates are then regioselectively halogenated and further diversified, resulting in a broad library of dipeptide isosteres with customizable features. Some of these compounds have demonstrated significant broad-spectrum antimicrobial activity, particularly against drug-resistant strains like *Staphylococcus aureus* and *Enterococcus faecalis*, with efficacy comparable to established antibiotics. Additionally, these isosteres can be converted into certain amino acids, which are easily incorporated into peptides or peptoids via solid-phase peptide synthesis, enabling the creation of heterocyclic backbone-containing peptides with improved rigidity, stability, and biological activity. What differentiates this technology is its highly modular and chemo-selective synthetic approach, which overcomes the limitations of traditional dipeptide isostere synthesis—often hampered by low yields and poor functional group tolerance. The platform’s ability to rapidly generate a diverse array of heterocyclic scaffolds allows for extensive structure–activity relationship studies and swift optimization of bioactive compounds. Its demonstrated antimicrobial efficacy against multidrug-resistant pathogens directly addresses the urgent need for new antibiotic scaffolds, while the seamless integration of its building blocks into standard peptide synthesis pipelines expands the toolkit for developing next-generation peptidomimetics and therapeutics. Furthermore, the technology’s compatibility with DNA-encoded libraries and broad applicability across pharmaceuticals, diagnostics, agriculture, and chemical biology make it a versatile and valuable solution for advancing drug discovery and biomedical research. 

                          https://suny.technologypublisher.com/files/sites/adobestock_84589964.jpeg
                          Photo for reference only, not a depiction of the invention.

                          Advantages:  
                          •    Enables modular, chemo-selective synthesis of structurally diverse heterocyclic dipeptide isosteres with broad functional group tolerance.
                          •    Generates a large library of compounds with tunable properties.
                          •    Demonstrates potent broad-spectrum antimicrobial activity against antibiotic-resistant pathogens such as Staphylococcus aureus and Enterococcus faecalis.
                          •    Facilitates conversion into heterocyclic amino acids compatible with solid-phase peptide synthesis, enabling creation of peptides with enhanced rigidity, stability, and biological activity.
                          •    Addresses urgent needs in antibiotic resistance and expands chemical diversity for peptidomimetic drug discovery and protein–protein interaction studies.
                          •    Integrates seamlessly with existing pharmaceutical, chemical biology, diagnostic, and agricultural applications, supporting diverse therapeutic and research uses.
                          •    Provides a scalable, robust synthetic platform that overcomes limitations of traditional dipeptide isostere synthesis methods. 

                          Applications:  
                          •    Next-generation antibiotic drug development
                          •    Peptidomimetic drug discovery
                          •    Protein–protein interaction inhibitor design
                          •    Stable peptide-based diagnostics
                          •    Antimicrobial coatings for surfaces 

                          Intellectual Property Summary:
                          Patent application filed

                          Stage of Development:
                          TRL 3

                          Licensing Status:
                          This technology is available for licensing.
                           

                          ]]>Mon, 04 May 2026 17:25:27 GMTIEA@rfsuny.orghttps://www.canberra-ip.com/tech/Structurally_and_Functionally_Diverse_Heterocyclic_Dipeptide_Isosteres_and_Their_Derivatives_as_Antimicrobial_Agents_and_Peptidomimetic_Building_Blocks160-2394Tue, 05 May 2026 17:23:55 GMTThis technology enables rapid, modular synthesis of diverse heterocyclic dipeptide isosteres with potent antimicrobial activity, which can be easily incorporated into peptides to create stable, bioactive molecules for drug discovery and therapeutic applications.Background:Technology Overview:https://suny.technologypublisher.com/files/sites/adobestock_84589964.jpegPhoto for reference only, not a depiction of the invention.Advantages: •    Generates a large library of compounds with tunable properties.
                          •    Demonstrates potent broad-spectrum antimicrobial activity against antibiotic-resistant pathogens such as Staphylococcus aureus and Enterococcus faecalis.
                          •    Facilitates conversion into heterocyclic amino acids compatible with solid-phase peptide synthesis, enabling creation of peptides with enhanced rigidity, stability, and biological activity.
                          •    Addresses urgent needs in antibiotic resistance and expands chemical diversity for peptidomimetic drug discovery and protein–protein interaction studies.
                          •    Integrates seamlessly with existing pharmaceutical, chemical biology, diagnostic, and agricultural applications, supporting diverse therapeutic and research uses.
                          •    Provides a scalable, robust synthetic platform that overcomes limitations of traditional dipeptide isostere synthesis methods.]]>Applications: •    Peptidomimetic drug discovery
                          •    Protein–protein interaction inhibitor design
                          •    Stable peptide-based diagnostics
                          •    Antimicrobial coatings for surfaces]]>Intellectual Property Summary:Patent application filedStage of Development:TRL 3Licensing Status:This technology is available for licensing.SujitSuwalAssoc. Prof.chemistrysuwals@buffalostate.edu716-878-9865OlgaNovikovaDr.Biologynovikoos@buffalostate.eduantibacterial, Bioactive heterocyclic amino esters and peptidomimetics, Chemo-selective synthesis of heterocyclic amino esters, iterative Buchwald Hartwig amination and Suzuki coupling, Technologies, PatrickNelsonLife Sciences IP Managerpatrick.nelson@rfsuny.org Buffalo State College| Technology Classifications > Drug Design and Synthesis]]>False